1. CPC Sections
  2. CPC Section A
  3. CPC Class A61
  4. CPC Subclass A61K
Printable version [PDF]
Version: 2024.08
Loading Scheme...
CPC
COOPERATIVE PATENT CLASSIFICATION
​​
A61K
PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J 3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) [2023-02]
NOTES

  • This subclass covers the following subject matter, whether set forth as a composition (mixture), process of preparing the composition or process of treating using the composition:
    • Drug or other biological compositions which are capable of:
      • preventing, alleviating, treating or curing abnormal or pathological conditions of the living body by such means as destroying a parasitic organism, or limiting the effect of the disease or abnormality by chemically altering the physiology of the host or parasite (biocides A01N 25/00 - A01N 65/00);
      • maintaining, increasing, decreasing, limiting, or destroying a physiological body function, e.g. vitamin compositions, sex sterilants, fertility inhibitors, growth promotors, or the like (sex sterilants for invertebrates, e.g. insects, A01N; plant growth regulators A01N 25/00 - A01N 65/00);
      • diagnosing a physiological condition or state by an in vivo test, e.g. X-ray contrast or skin patch test compositions (measuring or testing processes involving enzymes or microorganisms C12Q; in vitro testing of biological material, e.g. blood, urine, G01N, e.g. G01N 33/48)
    • Body treating compositions generally intended for deodorising, protecting, adorning or grooming the body, e.g. cosmetics, dentifrices, tooth filling materials.
  • Attention is drawn to the definitions of groups of chemical elements following the title of section C.
  • Attention is drawn to the notes in class C07, for example the notes following the title of the subclass C07D, setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in A61K.
  • In this subclass, with the exception of group A61K 8/00, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.
  • Therapeutic activity of medicinal preparations is further classified in subclass A61P. 
WARNINGS

​
A61K 6/00
Preparations for dentistry [2020-01]
NOTE

A61K 6/15
.
Compositions characterised by their physical properties [2020-01]
A61K 6/16
. .
Refractive index [2020-01]
A61K 6/17
. .
Particle size [2020-01]
A61K 6/18
. .
causing dental retraction, e.g. compositions for widening the sulcus for making dental impressions or removing teeth [2020-01]
A61K 6/19
. .
Self-expanding, e.g. for filling teeth [2020-01]
A61K 6/20
.
Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish [2020-01]
A61K 6/25
.
Compositions for detecting or measuring, e.g. of irregularities on natural or artificial teeth [2020-01]
A61K 6/30
.
Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives [2020-01]
A61K 6/35
. .
Preparations for stabilising dentures in the mouth [2020-01]
A61K 6/40
.
Primers (for dental adhesives A61K 6/30) [2020-01]
A61K 6/50
.
Preparations specially adapted for dental root treatment [2020-01]
A61K 6/52
. .
Cleaning; Disinfecting [2020-01]
A61K 6/54
. .
Filling; Sealing [2020-01]
A61K 6/56
. .
Apical treatment [2020-01]
A61K 6/58
. .
specially adapted for dental implants [2020-01]
A61K 6/60
.
comprising organic or organo-metallic additives [2020-01]
A61K 6/61
. .
Cationic, anionic or redox initiators [2020-01]
A61K 6/62
. .
Photochemical radical initiators [2020-01]
A61K 6/64
. .
Thermal radical initiators [2020-01]
A61K 6/65
. .
Dyes [2020-01]
A61K 6/66
. . .
Photochromic dyes [2020-01]
A61K 6/68
. . .
Thermochromic dyes [2020-01]
A61K 6/69
. .
Medicaments [2020-01]
A61K 6/70
.
comprising inorganic additives [2020-01]
A61K 6/71
. .
Fillers [2020-01]
A61K 6/72
. . .
comprising nitrogen-containing compounds [2020-01]
A61K 6/73
. . .
comprising sulfur-containing compounds [2020-01]
A61K 6/74
. . .
comprising phosphorus-containing compounds [2020-01]
A61K 6/75
. . . .
Apatite [2020-01]
A61K 6/76
. . .
comprising silicon-containing compounds [2020-01]
A61K 6/77
. . .
Glass [2020-01]
A61K 6/78
. .
Pigments [2020-01]
A61K 6/79
. .
Initiators [2020-01]
A61K 6/80
.
Preparations for artificial teeth, for filling teeth or for capping teeth [2020-01]
A61K 6/802
. .
comprising ceramics [2020-01]
A61K 6/804
. . .
comprising manganese oxide [2020-01]
A61K 6/807
. . .
comprising magnesium oxide [2020-01]
A61K 6/809
. . .
comprising beryllium oxide [2020-01]
A61K 6/811
. . .
comprising chromium oxide [2020-01]
A61K 6/813
. . .
comprising iron oxide [2020-01]
A61K 6/816
. . .
comprising titanium oxide [2020-01]
A61K 6/818
. . .
comprising zirconium oxide [2020-01]
A61K 6/82
. . .
comprising hafnium oxide [2020-01]
A61K 6/822
. . .
comprising rare earth metal oxides [2020-01]
A61K 6/824
. . .
comprising transition metal oxides [2020-01]
A61K 6/827
. . .
Leucite [2020-01]
A61K 6/829
. .
comprising cermet composites [2020-01]
A61K 6/831
. .
comprising non-metallic elements or compounds thereof, e.g. carbon [2020-01]
A61K 6/833
. . .
Glass-ceramic composites [2020-01]
A61K 6/836
. . .
Glass [2020-01]
A61K 6/838
. . .
Phosphorus compounds, e.g. apatite [2020-01]
A61K 6/84
. .
comprising metals or alloys [2020-01]
A61K 6/842
. . .
Rare earth metals [2020-01]
A61K 6/844
. . .
Noble metals [2020-01]
A61K 6/847
. . .
Amalgams [2020-01]
A61K 6/849
. .
comprising inorganic cements [2020-01]
A61K 6/851
. . .
Portland cements [2020-01]
A61K 6/853
. . .
Silicates [2020-01]
A61K 6/856
. . .
Pozzolans [2020-01]
A61K 6/858
. . .
Calcium sulfates, e.g, gypsum [2020-01]
A61K 6/86
. . .
Al-cements [2020-01]
A61K 6/862
. . .
Ca-Al-sulfate-cements [2020-01]
A61K 6/864
. . .
Phosphate cements (apatite A61K 6/838) [2020-01]
A61K 6/867
. . .
Ammonium cements [2020-01]
A61K 6/869
. . .
Zeolites [2020-01]
A61K 6/871
. . .
Quartz; SiO2 [2020-01]
A61K 6/873
. . .
Carbonates [2020-01]
A61K 6/876
. . .
Calcium oxide [2020-01]
A61K 6/878
. . .
Zirconium oxide [2020-01]
A61K 6/88
. . .
Chromium oxide [2020-01]
A61K 6/882
. . .
Carbides [2020-01]
A61K 6/884
. .
comprising natural or synthetic resins [2020-01]
A61K 6/887
. . .
Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds [2020-01]
A61K 6/889
. . . .
Polycarboxylate cements; Glass ionomer cements [2020-01]
A61K 6/891
. . .
Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds [2020-01]
A61K 6/893
. . . .
Polyurethanes [2020-01]
A61K 6/896
. . . .
Polyorganosilicon compounds [2020-01]
A61K 6/898
. . .
Polysaccharides [2020-01]
A61K 6/90
.
Compositions for taking dental impressions [2020-01]
​
A61K 8/00
Cosmetics or similar toiletry preparations [2023-02]
NOTES

  • Use of cosmetics or similar toiletry preparations is further classified in subclass A61Q.
  • {Use of cosmetics or similar toiletry preparations is mandatorily further classified in subclass A61Q.}
  • {Attention is drawn to the Notes in class C07, for example the notes following the title of subclass C07D, setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in group A61K 8/00.}
  • {Salts or complexes of organic compounds are classified according to the base compounds. If a complex is formed between two or more compounds, classification is made for each compound.}
​
A61K 8/02
.
characterised by special physical form [2015-01]
NOTE

  • In this group, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.
A61K 8/0204
. .
{Specific forms not provided for by any of groups A61K 8/0208 - A61K 8/14} [2016-05]
A61K 8/0208
. .
{Tissues; Wipes; Patches} [2013-01]
A61K 8/0212
. .
{Face masks} [2013-01]
A61K 8/0216
. .
{Solid or semisolid forms} [2013-01]
A61K 8/022
. . .
{Powders; Compacted Powders} [2013-01]
A61K 8/0225
. . . .
{Granulated powders} [2013-01]
A61K 8/0229
. . .
{Sticks} [2013-01]
A61K 8/0233
. . .
{Distinct layers, e.g. core/shell sticks} [2013-01]
A61K 8/0237
. . . .
{Striped compositions} [2013-01]
A61K 8/0241
. .
{Containing particulates characterized by their shape and/or structure (see also A61K 8/04, A61K 8/11, and A61K 8/14, further aspects are classified in A61K 2800/40 and subcodes)} [2013-01]
A61K 8/0245
. . .
{Specific shapes or structures not provided for by any of the groups of A61K 8/0241} [2013-01]
A61K 8/025
. . .
{Explicitly spheroidal or spherical shape} [2013-01]
A61K 8/0254
. . .
{Platelets; Flakes} [2013-01]
A61K 8/0258
. . . .
{Layered structure} [2013-01]
A61K 8/0262
. . . . .
{Characterized by the central layer} [2013-01]
A61K 8/0266
. . . . .
{Characterized by the sequence of layers} [2013-01]
A61K 8/027
. . .
{Fibers; Fibrils} [2013-01]
A61K 8/0275
. . .
{Containing agglomerated particulates} [2013-01]
A61K 8/0279
. . .
{Porous; Hollow} [2013-01]
A61K 8/0283
. . .
{Matrix particles} [2013-01]
A61K 8/0287
. . . .
{the particulate containing a solid-in-solid dispersion} [2013-01]
A61K 8/0291
. .
{Micelles} [2013-01]
A61K 8/0295
. .
{Liquid crystals} [2013-01]
A61K 8/03
. .
Liquid compositions with two or more distinct layers [2013-01]
A61K 8/04
. .
Dispersions; Emulsions [2013-01]
A61K 8/042
. . .
{Gels} [2013-01]
A61K 8/044
. . .
{Suspensions} [2013-01]
A61K 8/046
. . .
{Aerosols; Foams} [2013-01]
A61K 8/06
. . .
Emulsions [2013-01]
A61K 8/062
. . . .
{Oil-in-water emulsions} [2013-01]
A61K 8/064
. . . .
{Water-in-oil emulsions, e.g. Water-in-silicone emulsions} [2013-01]
A61K 8/066
. . . .
{Multiple emulsions, e.g. water-in-oil-in-water} [2013-01]
A61K 8/068
. . . .
{Microemulsions} [2013-01]
A61K 8/11
. .
Encapsulated compositions [2013-01]
A61K 8/14
. .
Liposomes; Vesicles [2013-01]
​
A61K 8/18
.
characterised by the composition [2015-01]
NOTE

  • In this group, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.
A61K 8/19
. .
containing inorganic ingredients [2013-01]
A61K 8/20
. . .
Halogens; Compounds thereof [2013-01]
A61K 8/21
. . . .
Fluorides; Derivatives thereof [2013-01]
A61K 8/22
. . .
Peroxides; Oxygen; Ozone [2013-01]
A61K 8/23
. . .
Sulfur; Selenium; Tellurium; Compounds thereof [2013-01]
A61K 8/24
. . .
Phosphorous; Compounds thereof [2013-01]
A61K 8/25
. . .
Silicon; Compounds thereof [2013-01]
A61K 8/26
. . .
Aluminium; Compounds thereof [2013-01]
A61K 8/27
. . .
Zinc; Compounds thereof [2013-01]
A61K 8/28
. . .
Zirconium; Compounds thereof [2013-01]
A61K 8/29
. . .
Titanium; Compounds thereof [2013-01]
A61K 8/30
. .
containing organic compounds [2013-01]
A61K 8/31
. . .
Hydrocarbons [2013-01]
A61K 8/315
. . . .
{Halogenated hydrocarbons} [2013-01]
A61K 8/33
. . .
containing oxygen [2013-01]
A61K 8/34
. . . .
Alcohols [2013-01]
A61K 8/342
. . . . .
{Alcohols having more than seven atoms in an unbroken chain} [2013-01]
A61K 8/345
. . . . .
{containing more than one hydroxy group} [2013-01]
A61K 8/347
. . . . .
{Phenols} [2013-01]
A61K 8/35
. . . .
Ketones, e.g. benzophenone [2013-01]
A61K 8/355
. . . . .
{Quinones} [2013-01]
A61K 8/36
. . . .
Carboxylic acids; Salts or anhydrides thereof [2013-01]
A61K 8/361
. . . . .
{Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof} [2013-01]
A61K 8/362
. . . . .
Polycarboxylic acids [2013-01]
A61K 8/365
. . . . .
Hydroxycarboxylic acids; Ketocarboxylic acids [2013-01]
A61K 8/368
. . . . .
with carboxyl groups directly bound to carbon atoms of aromatic rings [2019-05]
A61K 8/37
. . . .
Esters of carboxylic acids [2013-01]
A61K 8/375
. . . . .
{the alcohol moiety containing more than one hydroxy group} [2013-01]
A61K 8/38
. . . .
Percompounds, e.g. peracids [2013-01]
A61K 8/39
. . . .
Derivatives containing from 2 to 10 oxyalkylene groups [2013-11]
A61K 8/40
. . .
containing nitrogen (quinones containing nitrogen A61K 8/355) [2013-01]
A61K 8/41
. . . .
Amines [2013-01]
A61K 8/411
. . . . .
{Aromatic amines, i.e. where the amino group is directly linked to the aromatic nucleus} [2013-01]
A61K 8/413
. . . . .
{Indoanilines; Indophenol; Indoamines} [2013-01]
A61K 8/415
. . . . .
{Aminophenols} [2013-01]
A61K 8/416
. . . . .
{Quaternary ammonium compounds (A61K 8/35 takes precedence)} [2013-01]
A61K 8/418
. . . . .
{containing nitro groups} [2013-01]
A61K 8/42
. . . .
Amides [2013-01]
A61K 8/43
. . . .
Guanidines [2013-01]
A61K 8/44
. . . .
Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof [2013-01]
A61K 8/442
. . . . .
{substituted by amido group(s)} [2013-01]
A61K 8/445
. . . . .
{aromatic, i.e. the carboxylic acid directly linked to the aromatic ring} [2013-01]
A61K 8/447
. . . . .
{containing sulfur} [2013-01]
A61K 8/45
. . . .
Derivatives containing from 2 to 10 oxyalkylene groups [2013-11]
A61K 8/46
. . .
containing sulfur (A61K 8/44 takes precedence) [2013-01]
A61K 8/463
. . . .
{containing sulfuric acid derivatives, e.g. sodium lauryl sulfate} [2013-01]
A61K 8/466
. . . .
{containing sulfonic acid derivatives; Salts} [2013-01]
A61K 8/49
. . .
containing heterocyclic compounds [2013-01]
A61K 8/4906
. . . .
{with one nitrogen as the only hetero atom} [2013-01]
A61K 8/4913
. . . . .
{having five membered rings, e.g. pyrrolidone carboxylic acid} [2013-01]
A61K 8/492
. . . . . .
{having condensed rings, e.g. indol} [2013-01]
A61K 8/4926
. . . . .
{having six membered rings} [2013-01]
A61K 8/4933
. . . . .
{having sulfur as an exocyclic substituent, e.g. pyridinethione} [2013-01]
A61K 8/494
. . . .
{with more than one nitrogen as the only hetero atom} [2013-01]
A61K 8/4946
. . . . .
{Imidazoles or their condensed derivatives, e.g. benzimidazoles} [2013-01]
A61K 8/4953
. . . . .
{containing pyrimidine ring derivatives, e.g. minoxidil} [2013-01]
A61K 8/496
. . . . .
{Triazoles or their condensed derivatives, e.g. benzotriazoles} [2013-01]
A61K 8/4966
. . . . .
{Triazines or their condensed derivatives} [2013-01]
A61K 8/4973
. . . .
{with oxygen as the only hetero atom} [2013-01]
A61K 8/498
. . . . .
{having 6-membered rings or their condensed derivatives, e.g. coumarin} [2013-01]
A61K 8/4986
. . . .
{with sulfur as the only hetero atom} [2013-01]
A61K 8/4993
. . . .
{Derivatives containing from 2 to 10 oxyalkylene groups} [2013-11]
A61K 8/55
. . .
Phosphorus compounds [2013-01]
A61K 8/553
. . . .
{Phospholipids, e.g. lecithin} [2013-01]
A61K 8/556
. . . .
{Derivatives containing from 2 to 10 oxyalkylene groups} [2013-11]
A61K 8/58
. . .
containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus [2013-01]
A61K 8/585
. . . .
{Organosilicon compounds} [2013-01]
A61K 8/60
. . .
Sugars; Derivatives thereof [2013-01]
A61K 8/602
. . . .
{Glycosides, e.g. rutin} [2013-01]
A61K 8/604
. . . .
{Alkylpolyglycosides; Derivatives thereof, e.g. esters} [2013-01]
A61K 8/606
. . . .
{Nucleosides; Nucleotides; Nucleic acids} [2013-01]
A61K 8/608
. . . .
{Derivatives containing from 2 to 10 oxyalkylene groups} [2013-11]
​
A61K 8/63
. . .
Steroids; Derivatives thereof [2013-01]
NOTE

  • This group covers steroids, as defined in Note (1) after the title of subclass C07J.
A61K 8/64
. . .
Proteins; Peptides; Derivatives or degradation products thereof [2013-01]
A61K 8/645
. . . .
{Proteins of vegetable origin; Derivatives or degradation products thereof} [2013-01]
A61K 8/65
. . . .
Collagen; Gelatin; Keratin; Derivatives or degradation products thereof [2013-01]
A61K 8/66
. . . .
Enzymes [2013-01]
A61K 8/67
. . .
Vitamins [2013-01]
A61K 8/671
. . . .
{Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal} [2013-01]
A61K 8/673
. . . .
{Vitamin B group} [2013-01]
A61K 8/675
. . . . .
{Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde (tocopheryl nicotinate A61K 8/678)} [2013-01]
A61K 8/676
. . . .
{Ascorbic acid, i.e. vitamin C} [2013-01]
A61K 8/678
. . . .
{Tocopherol, i.e. vitamin E} [2013-01]
A61K 8/68
. . .
Sphingolipids, e.g. ceramides, cerebrosides, gangliosides [2013-01]
A61K 8/69
. . .
containing fluorine [2013-01]
A61K 8/70
. . . .
containing perfluoro groups, e.g. perfluoroethers [2013-01]
A61K 8/72
. .
containing organic macromolecular compounds [2013-01]
A61K 8/73
. . .
Polysaccharides [2013-01]
A61K 8/731
. . . .
{Cellulose; Quaternized cellulose derivatives} [2013-01]
A61K 8/732
. . . .
{Starch; Amylose; Amylopectin; Derivatives thereof} [2013-01]
A61K 8/733
. . . .
{Alginic acid; Salts thereof} [2013-01]
A61K 8/735
. . . .
{Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof} [2013-01]
A61K 8/736
. . . .
{Chitin; Chitosan; Derivatives thereof} [2013-01]
A61K 8/737
. . . .
{Galactomannans, e.g. guar; Derivatives thereof} [2013-01]
A61K 8/738
. . . .
{Cyclodextrins} [2013-01]
A61K 8/81
. . .
obtained by reactions involving only carbon-to-carbon unsaturated bonds [2013-01]
A61K 8/8105
. . . .
{Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers} [2013-01]
A61K 8/8111
. . . . .
{Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers} [2013-01]
A61K 8/8117
. . . . .
{Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers} [2013-01]
A61K 8/8123
. . . .
{Compositions of homopolymers or copolymers of compounds having one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers, e.g. PVC, PTFE} [2013-01]
A61K 8/8129
. . . .
{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers or esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers, e.g. polyvinylmethylether} [2013-01]
A61K 8/8135
. . . .
{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an acyloxy radical of a saturated carboxylic acid, of carbonic acid or of a haloformic acid; Compositions of derivatives of such polymers, e.g. vinyl esters (polyvinylacetate)} [2013-01]
A61K 8/8141
. . . .
{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers} [2013-01]
A61K 8/8147
. . . . .
{Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers} [2013-01]
A61K 8/8152
. . . . .
{Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers} [2013-01]
A61K 8/8158
. . . . .
{Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers} [2013-01]
A61K 8/8164
. . . .
{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)} [2013-01]
A61K 8/817
. . . .
{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)} [2013-01]
A61K 8/8176
. . . . .
{Homopolymers of N-vinyl-pyrrolidones. Compositions of derivatives of such polymers} [2013-01]
A61K 8/8182
. . . . .
{Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers} [2013-01]
A61K 8/8188
. . . .
{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bonds, and at least one being terminated by a bond to sulfur or by a hertocyclic ring containing sulfur; Compositions of derivatives of such polymers} [2013-01]
A61K 8/8194
. . . .
{Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Compositions of derivatives of such polymers} [2013-01]
A61K 8/84
. . .
obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds [2016-11]
A61K 8/85
. . . .
Polyesters [2013-01]
A61K 8/86
. . . .
Polyethers [2013-01]
A61K 8/87
. . . .
Polyurethanes [2013-01]
A61K 8/88
. . . .
Polyamides [2013-01]
A61K 8/89
. . . .
Polysiloxanes [2013-01]
A61K 8/891
. . . . .
saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone [2013-01]
A61K 8/892
. . . . . .
modified by a hydroxy group, e.g. dimethiconol [2013-01]
A61K 8/893
. . . . . .
modified by an alkoxy or aryloxy group, e.g. behenoxy dimethicone or stearoxy dimethicone [2013-01]
A61K 8/894
. . . . . .
modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol [2013-01]
A61K 8/895
. . . . .
containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone [2013-01]
A61K 8/896
. . . . .
containing atoms other than silicon, carbon, oxygen and hydrogen, e.g. dimethicone copolyol phosphate [2013-01]
A61K 8/897
. . . . . .
containing halogen, e.g. fluorosilicones [2013-01]
A61K 8/898
. . . . . .
containing nitrogen, e.g. amodimethicone, trimethyl silyl amodimethicone or dimethicone propyl PG-betaine [2013-01]
A61K 8/899
. . . . . .
containing sulfur, e.g. sodium PG-propyldimethicone thiosulfate copolyol [2013-01]
A61K 8/90
. . .
Block copolymers (A61K 8/89 takes precedence) [2013-01]
A61K 8/91
. . .
Graft copolymers (A61K 8/89 takes precedence) [2013-01]
A61K 8/92
. .
Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof [2013-01]
A61K 8/922
. . .
{of vegetable origin} [2013-01]
A61K 8/925
. . .
{of animal origin} [2013-01]
A61K 8/927
. . .
{of insects, e.g. shellac} [2013-01]
A61K 8/96
. .
containing materials, or derivatives thereof of undetermined constitution [2017-08]
A61K 8/965
. . .
{of inanimate origin} [2013-01]
A61K 8/97
. . .
from algae, fungi, lichens or plants; from derivatives thereof [2021-02]
A61K 8/9706
. . . .
Algae [2021-02]
A61K 8/9711
. . . . .
Phaeophycota or Phaeophyta [brown algae], e.g. Fucus [2021-02]
A61K 8/9717
. . . . .
Rhodophycota or Rhodophyta [red algae], e.g. Porphyra [2021-02]
A61K 8/9722
. . . . .
Chlorophycota or Chlorophyta [green algae], e.g. Chlorella [2021-02]
A61K 8/9728
. . . .
Fungi, e.g. yeasts [2021-02]
A61K 8/9733
. . . .
Lichens [2021-02]
A61K 8/9739
. . . .
Bryophyta [mosses] [2021-02]
A61K 8/9741
. . . .
Pteridophyta [ferns] [2021-02]
A61K 8/9749
. . . . .
Filicopsida or Pteridopsida [2017-08]
A61K 8/9755
. . . .
Gymnosperms [Coniferophyta] [2021-02]
A61K 8/9761
. . . . .
Cupressaceae [Cypress family], e.g. juniper or cypress [2017-08]
A61K 8/9767
. . . . .
Pinaceae [Pine family], e.g. pine or cedar [2017-08]
A61K 8/9771
. . . .
Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family] [2021-02]
A61K 8/9778
. . . .
Gnetophyta, e.g. Ephedraceae [Mormon-tea family] [2021-02]
A61K 8/9783
. . . .
Angiosperms [Magnoliophyta] [2021-02]
A61K 8/9789
. . . . .
Magnoliopsida [dicotyledons] [2017-08]
A61K 8/9794
. . . . .
Liliopsida [monocotyledons] [2017-08]
A61K 8/98
. . .
of animal origin [2013-01]
A61K 8/981
. . . .
{of mammals or bird} [2013-01]
A61K 8/982
. . . . .
{Reproductive organs; Embryos, Eggs} [2013-01]
A61K 8/983
. . . . .
{Blood, e.g. plasma} [2013-01]
A61K 8/985
. . . . .
{Skin or skin outgrowth, e.g. hair, nails} [2013-01]
A61K 8/986
. . . . .
{Milk; Derivatives thereof, e.g. butter} [2013-01]
A61K 8/987
. . . .
{of species other than mammals or birds} [2013-01]
A61K 8/988
. . . . .
{Honey; Royal jelly, Propolis} [2013-01]
A61K 8/99
. . .
from microorganisms other than algae or fungi, e.g. protozoa or bacteria [2021-02]
​
A61K 9/00
Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K 49/18; preparations containing radioactive substances A61K 51/12)} [2021-05]
NOTE

  • Among the one-dot groups of A61K 9/00, classification is not made in the last appropriate place.
    A61K 9/00 is subdivided according to the following concepts: Where relevant, documents are classified in more than one of these subdivisions.
A61K 9/0002
.
{Galenical forms characterised by the drug release technique; Application systems commanded by energy} [2013-01]
A61K 9/0004
. .
{Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas} [2013-01]
A61K 9/0007
. .
{Effervescent (A61K 9/0065 takes precedence)} [2013-01]
A61K 9/0009
. .
{involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis (microelectromechanical systems A61K 9/0097)} [2013-01]
A61K 9/0012
.
{Galenical forms characterised by the site of application} [2013-01]
A61K 9/0014
. .
{Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K 47/00; A61K 9/0009, A61K 9/0021, A61K 9/7015, A61K 9/7023 take precedence; cosmetic preparations A61K 8/00, A61Q; preparations for wound dressings or bandages A61L 26/00)} [2013-01]
A61K 9/0017
. . .
{Non-human animal skin, e.g. pour-on, spot-on} [2013-01]
A61K 9/0019
. .
{Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K 47/00)} [2013-01]
A61K 9/0021
. . .
{Intradermal administration, e.g. through microneedle arrays, needleless injectors (mechanical aspects A61M)} [2013-01]
A61K 9/0024
. . .
{Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K 9/0019; brain implants A61K 9/0085; (coated) prostheses, catheters or stents A61L)} [2016-08]
A61K 9/0026
. . .
{Blood substitute; Oxygen transporting formulations; Plasma extender} [2013-01]
A61K 9/0029
. . .
{Parenteral nutrition; Parenteral nutrition compositions as drug carriers} [2013-01]
A61K 9/0031
. .
{Rectum, anus} [2013-01]
A61K 9/0034
. .
{Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants} [2013-01]
A61K 9/0036
. . .
{Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms} [2013-01]
A61K 9/0039
. . .
{Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception} [2013-01]
A61K 9/0041
. .
{Mammary glands, e.g. breasts, udder; Intramammary administration} [2013-01]
A61K 9/0043
. .
{Nose} [2013-01]
A61K 9/0046
. .
{Ear} [2013-01]
A61K 9/0048
. .
{Eye, e.g. artificial tears} [2013-01]
A61K 9/0051
. . .
{Ocular inserts, ocular implants} [2013-01]
A61K 9/0053
. .
{Mouth and digestive tract, i.e. intraoral and peroral administration (rectal administration A61K 9/0031)} [2013-01]
A61K 9/0056
. . .
{Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals} [2013-01]
A61K 9/0058
. . . .
{Chewing gums (non-medicinal aspects, preparing chewing gum A23G 4/00; chewing gum for care of the teeth or oral cavity, e.g. with breath freshener A61Q 11/00)} [2013-01]
A61K 9/006
. . .
{Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays} [2013-01]
A61K 9/0063
. . .
{Periodont} [2013-01]
A61K 9/0065
. . .
{Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus} [2013-01]
A61K 9/0068
. . .
{Rumen, e.g. rumen bolus} [2013-01]
A61K 9/007
. .
{Pulmonary tract; Aromatherapy} [2013-01]
A61K 9/0073
. . .
{Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K 9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K 9/007; devices A61M)} [2013-01]
A61K 9/0075
. . . .
{for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles} [2018-01]
A61K 9/0078
. . . .
{for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions} [2013-01]
A61K 9/008
. . . .
{comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]} [2013-01]
A61K 9/0082
. . .
{Lung surfactant, artificial mucus} [2013-01]
A61K 9/0085
. .
{Brain, e.g. brain implants; Spinal cord} [2013-01]
A61K 9/0087
.
{Galenical forms not covered by A61K 9/02 - A61K 9/7023} [2016-05]
A61K 9/009
. .
{Sachets, pouches characterised by the material or function of the envelope (with gastric retention A61K 9/0065; sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink A61K 9/0095)} [2013-01]
A61K 9/0092
. .
{Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes} [2021-05]
A61K 9/0095
. .
{Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K 9/0007 takes precedence; eatable gels or foams A61K 9/0056; oral mucosa adhesive forms A61K 9/006)} [2013-01]
A61K 9/0097
. .
{Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips (intradermal microneedle arrays A61K 9/0021; MEMS in general B81B 7/02)} [2013-01]
A61K 9/02
.
Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J 3/08; devices for introducing into the body A61M 31/00) [2013-01]
A61K 9/025
. .
{characterised by shape or structure, e.g. hollow layered, coated} [2013-01]
A61K 9/06
.
Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K 47/00)} [2020-01]
A61K 9/08
.
Solutions {(composition of solutions A61K 47/00)} [2020-01]
A61K 9/10
.
Dispersions; Emulsions {(A61K 9/06 takes precedence; composition of dispersions, emulsions A61K 47/00)} [2020-01]
A61K 9/107
. .
Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K 47/00)} [2020-01]
A61K 9/1075
. . .
{Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K 9/0026 takes precedence)} [2013-01]
A61K 9/113
. . .
Multiple emulsions, e.g. oil-in-water-in-oil {(A61K 9/0026 takes precedence)} [2017-08]
A61K 9/12
. .
Aerosols; Foams {(A61K 9/0043, A61K 9/0056, A61K 9/006, A61K 9/0073 take precedence; spray-films A61K 9/7015)} [2013-01]
A61K 9/122
. . .
{Foams; Dry foams (edible foams A61K 9/0056)} [2013-01]
A61K 9/124
. . .
{characterised by the propellant} [2013-01]
A61K 9/127
. .
Liposomes [2013-01]
A61K 9/1271
. . .
{Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers (liposome as conjugate A61K 47/6911)} [2017-08]
A61K 9/1272
. . . .
{with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids (with cholesterol as the only non-phosphatidyl surfactant A61K 9/127; lipids as modifying agent A61K 47/543)} [2017-08]
A61K 9/1273
. . . .
{Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances (polymers grafted or coated on phosphatidyl liposomes A61K 9/1271, on non-phosphatidyl liposomes A61K 9/1272)} [2013-01]
A61K 9/1274
. . .
{Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases} [2013-01]
A61K 9/1275
. . .
{Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof} [2013-01]
A61K 9/1276
. . .
{Globules of milk or constituents thereof} [2013-01]
A61K 9/1277
. . .
{Processes for preparing; Proliposomes} [2013-01]
A61K 9/1278
. . . .
{Post-loading, e.g. by ion or pH gradient} [2013-01]
A61K 9/14
.
Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K 9/16; microcapsules A61K 9/50; nanocapsules, nanoparticles of the matrix type A61K 9/51)} [2013-01]
A61K 9/141
. .
{Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers ((co) spray-dried products A61K 9/16, (co) lyophilised products A61K 9/19; the carrier being chemically bound to the active ingredient A61K 47/50)} [2017-08]
A61K 9/143
. . .
{with inorganic compounds} [2013-01]
A61K 9/145
. . .
{with organic compounds} [2013-01]
A61K 9/146
. . .
{with organic macromolecular compounds} [2013-01]
A61K 9/148
. . .
{with compounds of unknown constitution, e.g. material from plants or animals (with oils, fats, waxes, shellac A61K 9/145)} [2013-01]
A61K 9/16
. .
Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K 9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K 9/50; mixture of different granules, microcapsules, (coated) microparticles A61K 9/5084; nanoparticles A61K 9/51)} [2017-08]
A61K 9/1605
. . .
{Excipients; Inactive ingredients} [2013-01]
A61K 9/1611
. . . .
{Inorganic compounds} [2013-01]
A61K 9/1617
. . . .
{Organic compounds, e.g. phospholipids, fats} [2013-01]
A61K 9/1623
. . . . .
{Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules} [2013-01]
A61K 9/1629
. . . .
{Organic macromolecular compounds} [2013-01]
A61K 9/1635
. . . . .
{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates} [2013-01]
A61K 9/1641
. . . . .
{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers} [2013-01]
A61K 9/1647
. . . . . .
{Polyesters, e.g. poly(lactide-co-glycolide)} [2013-01]
A61K 9/1652
. . . . .
{Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K 9/1623)} [2013-01]
A61K 9/1658
. . . . .
{Proteins, e.g. albumin, gelatin} [2013-01]
A61K 9/1664
. . . .
{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K 9/1617)} [2013-01]
A61K 9/167
. . .
{with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface (with further drug-free outer coating A61K 9/5073)} [2013-01]
A61K 9/1676
. . . .
{having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K 9/141; with further drug-free outer coating A61K 9/5078; drug conjugated to non-active particles A61K 47/6921)} [2017-08]
A61K 9/1682
. . .
{Processes} [2013-01]
A61K 9/1688
. . . .
{resulting in pure drug agglomerate optionally containing up to 5% of excipient} [2013-01]
A61K 9/1694
. . . .
{resulting in granules or microspheres of the matrix type containing more than 5% of excipient} [2013-01]
A61K 9/19
. .
lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K 9/14; granules or pellets made by lyphilisation A61K 9/1682; solid oral dosage forms made by lyophilisation A61K 9/2095; lyophilisation additives A61K 47/00)} [2017-08]
A61K 9/20
.
Pills, tablets, {discs, rods (A61K 9/0004, A61K 9/0007, A61K 9/0056, A61K 9/0065 take precedence; for reconstitution of a drink A61K 9/0095)} [2013-01]
A61K 9/2004
. .
{Excipients; Inactive ingredients} [2013-01]
A61K 9/2009
. . .
{Inorganic compounds} [2013-01]
A61K 9/2013
. . .
{Organic compounds, e.g. phospholipids, fats} [2013-01]
A61K 9/2018
. . . .
{Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates} [2013-01]
A61K 9/2022
. . .
{Organic macromolecular compounds} [2013-01]
A61K 9/2027
. . . .
{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates} [2013-01]
A61K 9/2031
. . . .
{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers} [2013-01]
A61K 9/2036
. . . . .
{Silicones; Polysiloxanes} [2013-01]
A61K 9/204
. . . . .
{Polyesters, e.g. poly(lactide-co-glycolide)} [2013-01]
A61K 9/2045
. . . . .
{Polyamides; Polyaminoacids, e.g. polylysine} [2013-01]
A61K 9/205
. . . .
{Polysaccharides, e.g. alginate, gums; Cyclodextrin} [2013-01]
A61K 9/2054
. . . . .
{Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} [2013-01]
A61K 9/2059
. . . . .
{Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin} [2013-01]
A61K 9/2063
. . . .
{Proteins, e.g. gelatin} [2013-01]
A61K 9/2068
. . .
{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K 9/2013)} [2013-01]
A61K 9/2072
. .
{characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K 9/0004, A61K 9/0056, A61K 9/0065 take precedence)} [2013-01]
A61K 9/2077
. . .
{Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets} [2013-01]
A61K 9/2081
. . . .
{with microcapsules or coated microparticles according to A61K 9/50} [2013-01]
A61K 9/2086
. . .
{Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K 9/28)} [2013-01]
A61K 9/209
. . . .
{containing drug in at least two layers or in the core and in at least one outer layer} [2013-01]
A61K 9/2095
. .
{Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing (mechanical aspects A61J 3/00)} [2013-01]
A61K 9/28
. .
Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K 9/2072 takes precedence, e.g. partially coated tablets A61K 9/2072, coated multilayer tablets A61K 9/2086, tablets with drug-coated core A61K 9/209)} [2016-08]
A61K 9/2806
. . .
{Coating materials} [2013-01]
A61K 9/2813
. . . .
{Inorganic compounds} [2013-01]
A61K 9/282
. . . .
{Organic compounds, e.g. fats} [2013-01]
A61K 9/2826
. . . . .
{Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof} [2013-01]
A61K 9/2833
. . . .
{Organic macromolecular compounds} [2013-01]
A61K 9/284
. . . . .
{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone} [2013-01]
A61K 9/2846
. . . . . .
{Poly(meth)acrylates} [2013-01]
A61K 9/2853
. . . . .
{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)} [2013-01]
A61K 9/286
. . . . .
{Polysaccharides, e.g. gums; Cyclodextrin} [2013-01]
A61K 9/2866
. . . . . .
{Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose} [2013-01]
A61K 9/2873
. . . . .
{Proteins, e.g. gelatin} [2013-01]
A61K 9/288
. . . .
{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K 9/282)} [2013-01]
A61K 9/2886
. . .
{having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K 9/209)} [2013-01]
A61K 9/2893
. . .
{Tablet coating processes (mechanical aspects A61J 3/06)} [2013-01]
A61K 9/48
.
Preparations in capsules, e.g. of gelatin, of chocolate {(A61K 9/0004 takes precedence; bite capsules A61K 9/0056)} [2017-08]
A61K 9/4808
. .
{characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K 9/16; filled with microcapsules or coated microparticles A61K 9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K 9/5084)} [2013-01]
A61K 9/4816
. .
{Wall or shell material} [2013-01]
A61K 9/4825
. . .
{Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K 9/4816)} [2013-01]
A61K 9/4833
. .
{Encapsulating processes; Filling of capsules (mechanical aspects A61J 3/07)} [2013-01]
A61K 9/4841
. .
{Filling excipients; Inactive ingredients} [2013-01]
A61K 9/485
. . .
{Inorganic compounds} [2013-01]
A61K 9/4858
. . .
{Organic compounds} [2013-01]
A61K 9/4866
. . .
{Organic macromolecular compounds} [2013-01]
A61K 9/4875
. . .
{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K 9/4858)} [2013-01]
A61K 9/4883
. .
{Capsule finishing, e.g. dyeing, aromatising, polishing} [2013-01]
A61K 9/4891
. .
{Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K 9/4808; osmotic devices A61K 9/0004)} [2013-01]
A61K 9/50
. .
Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K 9/2081 takes precedence; particles with a single coating comprising drug A61K 9/167)} [2013-01]
A61K 9/5005
. . .
{Wall or coating material} [2013-01]
A61K 9/501
. . . .
{Inorganic compounds} [2013-01]
A61K 9/5015
. . . .
{Organic compounds, e.g. fats, sugars} [2013-01]
A61K 9/5021
. . . .
{Organic macromolecular compounds} [2013-01]
A61K 9/5026
. . . . .
{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates} [2013-01]
A61K 9/5031
. . . . .
{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)} [2013-01]
A61K 9/5036
. . . . .
{Polysaccharides, e.g. gums, alginate; Cyclodextrin} [2013-01]
A61K 9/5042
. . . . . .
{Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose} [2013-01]
A61K 9/5047
. . . . . . .
{Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose} [2013-01]
A61K 9/5052
. . . . .
{Proteins, e.g. albumin} [2013-01]
A61K 9/5057
. . . . . .
{Gelatin} [2013-01]
A61K 9/5063
. . . .
{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K 9/5015)} [2013-01]
A61K 9/5068
. . . . .
{Cell membranes or bacterial membranes enclosing drugs (with additional exogenous lipids A61K 9/127; virus envelopes A61K 9/5184)} [2013-01]
A61K 9/5073
. . .
{having two or more different coatings optionally including drug-containing subcoatings} [2013-01]
A61K 9/5078
. . . .
{with drug-free core} [2013-01]
A61K 9/5084
. . .
{Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K 9/16 or A61K 9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K 9/2077)} [2013-01]
A61K 9/5089
. . .
{Processes} [2013-01]
A61K 9/5094
. . .
{Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting} [2018-01]
A61K 9/51
. . .
Nanocapsules; {Nanoparticles; (nanotubes A61K 9/0092; polymeric micelles A61K 9/1075; polymersomes A61K 9/1273; pure drug nanoparticles A61K 9/14; drug nanoparticles with adsorbed surface modifiers A61K 9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K 47/50; preparations for in vivo diagnosis A61K 49/00; with radioactive substances A61K 51/00)} [2017-08]
A61K 9/5107
. . . .
{Excipients; Inactive ingredients} [2013-01]
A61K 9/5115
. . . . .
{Inorganic compounds} [2013-01]
A61K 9/5123
. . . . .
{Organic compounds, e.g. fats, sugars} [2013-01]
A61K 9/513
. . . . .
{Organic macromolecular compounds; Dendrimers} [2013-01]
A61K 9/5138
. . . . . .
{obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates} [2013-01]
A61K 9/5146
. . . . . .
{obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides} [2013-01]
A61K 9/5153
. . . . . . .
{Polyesters, e.g. poly(lactide-co-glycolide)} [2013-01]
A61K 9/5161
. . . . . .
{Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin} [2013-01]
A61K 9/5169
. . . . . .
{Proteins, e.g. albumin, gelatin} [2013-01]
A61K 9/5176
. . . . .
{Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K 9/5123)} [2013-01]
A61K 9/5184
. . . . . .
{Virus capsids or envelopes enclosing drugs (with additional exogenous lipids A61K 9/127; bacterial membranes A61K 9/5068)} [2013-01]
A61K 9/5192
. . . .
{Processes} [2013-01]
A61K 9/70
.
Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K 9/0092)} [2021-05]
A61K 9/7007
. .
{Drug-containing films, membranes or sheets (A61K 9/0041, A61K 9/0043, A61K 9/006, A61K 9/0063 take precedence)} [2013-01]
A61K 9/7015
. .
{Drug-containing film-forming compositions, e.g. spray-on} [2013-01]
A61K 9/7023
. .
{Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K 9/0009; microneedle arrays A61K 9/0021; buccal patches A61K 9/006)} [2013-01]
A61K 9/703
. . .
{characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches} [2013-01]
A61K 9/7038
. . . .
{Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer} [2013-01]
A61K 9/7046
. . . . .
{the adhesive comprising macromolecular compounds} [2013-01]
A61K 9/7053
. . . . . .
{obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene} [2013-01]
A61K 9/7061
. . . . . . .
{Polyacrylates} [2013-01]
A61K 9/7069
. . . . . .
{obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide} [2013-01]
A61K 9/7076
. . . . .
{the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins} [2013-01]
A61K 9/7084
. . . .
{Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches} [2013-01]
A61K 9/7092
. . . .
{Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs} [2013-01]
​
A61K 31/00
Medicinal preparations containing organic active ingredients [2023-05]
NOTES

  • {When classifying in groups A61K 31/00 - A61K 41/00 the symbol A61K 2300/00 may be added, using Combination Sets, to indicate a mixture of active ingredients.}
  • {In the preparation of new organic compounds and their use in medicinal preparations, classification is only made in the relevant subclasses C07C - C07J according to the type of compound. However, the inventions dealing with medicinal preparations containing at least two active organic ingredients are always classified in this group in addition to the classification for the type of compounds in C07C - C07J.}
  • {Attention is drawn to the notes in class C07, particularly to the definition of steroids given in Note (1) following the title of C07J and to the definition of carbohydrates and sugars given in the notes following the title of C07H.}
  • {According to the last place rule, organic active compounds forming salts with heavy metals should be classified in A61K 33/24 - A61K 33/38 and not in subgroups A61K 31/28 - A61K 31/32, A61K 31/555 or A61K 31/714. This does not apply to complexes, as apparent from the A61K 31/00 scheme, wherein the complexes hemin and hematin are classified in A61K 31/555 and cyanocobalamin in A61K 31/714. If a complex is formed between two or more active compounds, then they are classified according to all compounds forming the complexes followed by the symbol A61K 2300/00 (i.e. as a mixture of active organic compounds).}
A61K 31/01
.
Hydrocarbons [2013-01]
A61K 31/015
. .
carbocyclic [2013-01]
A61K 31/02
.
Halogenated hydrocarbons [2013-01]
A61K 31/025
. .
carbocyclic [2013-01]
A61K 31/03
. . .
aromatic [2013-01]
A61K 31/035
. .
having aliphatic unsaturation [2013-01]
A61K 31/04
.
Nitro compounds [2013-01]
A61K 31/045
.
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates [2013-01]
A61K 31/047
. .
having two or more hydroxy groups, e.g. sorbitol [2013-01]
​
A61K 31/05
. .
Phenols {(cannabinoids A61K 31/658)} [2023-05]
WARNING

  • Group A61K 31/05 is impacted by reclassification into group A61K 31/658.
    All groups listed in this Warning should be considered in order to perform a complete search.
A61K 31/055
. . .
the aromatic ring being substituted by halogen [2013-01]
A61K 31/06
. . .
the aromatic ring being substituted by nitro groups [2013-01]
A61K 31/065
. .
Diphenyl-substituted acyclic alcohols [2013-01]
A61K 31/07
. .
Retinol compounds, e.g. vitamin A (retinoic acids A61K 31/203) [2013-01]
A61K 31/075
.
Ethers or acetals [2013-01]
A61K 31/08
. .
acyclic, e.g. paraformaldehyde [2013-01]
A61K 31/085
. .
having an ether linkage to aromatic ring nuclear carbon [2013-01]
A61K 31/09
. . .
having two or more such linkages [2013-01]
A61K 31/095
.
Sulfur, selenium, or tellurium compounds, e.g. thiols [2013-01]
A61K 31/10
. .
Sulfides; Sulfoxides; Sulfones [2013-01]
A61K 31/105
. .
Persulfides (thiuram disulfides A61K 31/145; thiosulfonic acids A61K 31/185) [2013-01]
A61K 31/11
.
Aldehydes [2013-01]
A61K 31/115
. .
Formaldehyde [2013-01]
A61K 31/12
.
Ketones [2013-01]
A61K 31/121
. .
acyclic [2013-01]
A61K 31/122
. .
having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin [2013-01]
A61K 31/125
. . .
Camphor; Nuclear substituted derivatives thereof [2013-01]
A61K 31/13
.
Amines {(A61K 31/04 takes precedence)} [2013-01]
A61K 31/131
. .
acyclic [2017-08]
A61K 31/132
. .
having two or more amino groups, e.g. spermidine, putrescine [2013-01]
A61K 31/133
. .
having hydroxy groups, e.g. sphingosine [2013-01]
A61K 31/135
. .
having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K 31/137)} [2016-08]
A61K 31/136
. . .
having the amino group directly attached to the aromatic ring, e.g. benzeneamine [2013-01]
A61K 31/137
. . .
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} [2017-08]
A61K 31/138
. . .
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K 31/165; pindolol A61K 31/404; timolol A61K 31/5377) [2017-08]
A61K 31/14
. .
Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K 31/205) [2013-01]
A61K 31/145
. .
having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K 31/155) [2017-08]
A61K 31/15
. .
Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)} [2017-08]
A61K 31/155
. .
Amidines (Image), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) [2017-08]
A61K 31/16
.
Amides, e.g. hydroxamic acids [2013-01]
A61K 31/164
. .
of a carboxylic acid with an aminoalcohol, e.g. ceramides [2017-08]
A61K 31/165
. .
having aromatic rings, e.g. colchicine, atenolol, progabide [2013-01]
A61K 31/166
. . .
having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol [2013-01]
A61K 31/167
. . .
having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol [2013-01]
A61K 31/17
. .
having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K 31/155; sulfonylureas A61K 31/64) [2017-08]
A61K 31/175
. . .
having the group Image , >N—C(O)—N=N— orImage , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof [2017-08]
A61K 31/18
. .
Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K 31/63) [2013-01]
​
A61K 31/185
.
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K 31/16; peroxy acids A61K 31/327) [2023-05]
NOTE

  • Cyclic anhydrides are considered to be heterocyclic rings
A61K 31/19
. .
Carboxylic acids, e.g. valproic acid (salicylic acid A61K 31/60) [2017-08]
A61K 31/191
. . .
having two or more hydroxy groups, e.g. gluconic acid [2013-01]
​
A61K 31/192
. . .
having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K 31/658)} [2023-05]
WARNING

  • Group A61K 31/192 is impacted by reclassification into group A61K 31/658.
    All groups listed in this Warning should be considered in order to perform a complete search.
A61K 31/194
. . .
having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid [2013-01]
A61K 31/195
. . .
having an amino group [2013-01]
A61K 31/196
. . . .
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil [2013-01]
A61K 31/197
. . . .
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K 31/205) [2024-01]
A61K 31/198
. . . . .
Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K 31/205; proline A61K 31/401; tryptophan A61K 31/405; histidine A61K 31/4172; peptides not degraded to individual amino acids A61K 38/00) [2024-01]
A61K 31/20
. . .
having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids [2013-01]
A61K 31/201
. . . .
having one or two double bonds, e.g. oleic, linoleic acids [2013-01]
A61K 31/202
. . . .
having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K 31/557) [2013-01]
A61K 31/203
. . . .
Retinoic acids {; Salts thereof} [2023-08]
A61K 31/205
. .
Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine [2013-01]
A61K 31/21
.
Esters, e.g. nitroglycerine, selenocyanates [2013-01]
A61K 31/215
. .
of carboxylic acids [2013-01]
A61K 31/216
. . .
of acids having aromatic rings, e.g. benactizyne, clofibrate [2013-01]
A61K 31/22
. . .
of acyclic acids, e.g. pravastatin [2013-01]
A61K 31/221
. . . .
with compounds having an amino group, e.g. acetylcholine, acetylcarnitine [2013-01]
A61K 31/222
. . . .
with compounds having aromatic groups, e.g. dipivefrine, ibopamine [2013-01]
A61K 31/223
. . . .
of alpha-aminoacids [2013-01]
A61K 31/225
. . . .
Polycarboxylic acids [2013-01]
A61K 31/23
. . . .
of acids having a carboxyl group bound to a chain of seven or more carbon atoms [2013-01]
A61K 31/231
. . . . .
having one or two double bonds [2013-01]
A61K 31/232
. . . . .
having three or more double bonds, e.g. etretinate [2013-01]
A61K 31/235
. . .
having an aromatic ring attached to a carboxyl group [2013-01]
A61K 31/24
. . . .
having an amino or nitro group [2013-01]
A61K 31/245
. . . . .
Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K 31/60) [2013-01]
A61K 31/25
. . .
with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol [2013-01]
A61K 31/255
. .
of sulfoxy acids or sulfur analogues thereof [2013-01]
A61K 31/26
. .
Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters [2017-08]
A61K 31/265
. .
of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid [2013-01]
A61K 31/27
. .
of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine [2013-01]
A61K 31/275
.
Nitriles; Isonitriles [2013-01]
A61K 31/277
. .
having a ring, e.g. verapamil [2013-01]
A61K 31/28
.
Compounds containing heavy metals [2013-01]
A61K 31/282
. .
Platinum compounds [2013-01]
A61K 31/285
. .
Arsenic compounds [2013-01]
A61K 31/29
. .
Antimony or bismuth compounds [2013-01]
A61K 31/295
. .
Iron group metal compounds [2013-01]
A61K 31/30
. .
Copper compounds [2013-01]
A61K 31/305
. .
Mercury compounds [2013-01]
A61K 31/31
. . .
containing nitrogen [2013-01]
A61K 31/315
. .
Zinc compounds [2013-01]
A61K 31/32
. .
Tin compounds [2013-01]
A61K 31/325
.
Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K 31/145) [2013-01]
A61K 31/327
.
Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids [2013-01]
A61K 31/33
.
Heterocyclic compounds [2013-01]
A61K 31/335
. .
having oxygen as the only ring hetero atom, e.g. fungichromin [2013-01]
A61K 31/336
. . .
having three-membered rings, e.g. oxirane, fumagillin [2013-01]
A61K 31/337
. . .
having four-membered rings, e.g. taxol [2013-01]
A61K 31/34
. . .
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide [2013-01]
A61K 31/341
. . . .
not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine [2013-01]
A61K 31/343
. . . .
condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone [2013-01]
A61K 31/345
. . . .
Nitrofurans (nitrofurantoin A61K 31/4178) [2013-01]
A61K 31/35
. . .
having six-membered rings with one oxygen as the only ring hetero atom [2013-01]
A61K 31/351
. . . .
not condensed with another ring [2013-01]
​
A61K 31/352
. . . .
condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K 31/658)} [2023-05]
WARNING

  • Group A61K 31/352 is impacted by reclassification into group A61K 31/658.
    All groups listed in this Warning should be considered in order to perform a complete search.
A61K 31/353
. . . . .
3,4-Dihydrobenzopyrans, e.g. chroman, catechin [2013-01]
A61K 31/355
. . . . . .
Tocopherols, e.g. vitamin E [2013-01]
A61K 31/357
. . .
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel [2013-01]
A61K 31/36
. . . .
Compounds containing methylenedioxyphenyl groups, e.g. sesamin [2014-02]
A61K 31/365
. . .
Lactones [2013-01]
A61K 31/366
. . . .
having six-membered rings, e.g. delta-lactones [2013-01]
A61K 31/37
. . . . .
Coumarins, e.g. psoralen [2013-01]
A61K 31/375
. . . .
Ascorbic acid, i.e. vitamin C; Salts thereof [2013-01]
A61K 31/38
. .
having sulfur as a ring hetero atom [2013-01]
A61K 31/381
. . .
having five-membered rings [2013-01]
A61K 31/382
. . .
having six-membered rings, e.g. thioxanthenes (thiothixene A61K 31/496) [2022-01]
A61K 31/385
. . .
having two or more sulfur atoms in the same ring [2013-01]
A61K 31/39
. . .
having oxygen in the same ring [2013-01]
A61K 31/395
. .
having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins [2022-01]
A61K 31/396
. . .
having three-membered rings, e.g. aziridine [2016-11]
A61K 31/397
. . .
having four-membered rings, e.g. azetidine [2013-01]
A61K 31/40
. . .
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil [2013-01]
A61K 31/401
. . . .
Proline; Derivatives thereof, e.g. captopril [2013-01]
A61K 31/4015
. . . .
having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide [2013-01]
A61K 31/402
. . . .
1-aryl substituted, e.g. piretanide [2013-01]
A61K 31/4025
. . . .
not condensed and containing further heterocyclic rings, e.g. cromakalim [2013-01]
A61K 31/403
. . . .
condensed with carbocyclic rings, e.g. carbazole [2013-01]
A61K 31/4035
. . . . .
Isoindoles, e.g. phthalimide [2013-01]
A61K 31/404
. . . . .
Indoles, e.g. pindolol [2013-01]
A61K 31/4045
. . . . . .
Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin [2013-01]
A61K 31/405
. . . . . .
Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin [2013-01]
A61K 31/407
. . . .
condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine [2013-01]
A61K 31/409
. . . .
having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K 31/555) [2017-08]
A61K 31/41
. . .
having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole [2013-01]
A61K 31/415
. . . .
1,2-Diazoles [2013-01]
A61K 31/4152
. . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone [2013-01]
A61K 31/4155
. . . . .
non condensed and containing further heterocyclic rings [2013-01]
A61K 31/416
. . . . .
condensed with carbocyclic ring systems, e.g. indazole [2013-01]
A61K 31/4162
. . . . .
condensed with heterocyclic ring systems [2013-01]
A61K 31/4164
. . . .
1,3-Diazoles [2013-01]
A61K 31/4166
. . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin [2013-01]
A61K 31/4168
. . . . .
having a nitrogen attached in position 2, e.g. clonidine [2013-01]
A61K 31/417
. . . . .
Imidazole-alkylamines, e.g. histamine, phentolamine [2013-01]
A61K 31/4172
. . . . .
Imidazole-alkanecarboxylic acids, e.g. histidine [2013-01]
A61K 31/4174
. . . . .
Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole [2013-01]
A61K 31/4178
. . . . .
not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin [2013-01]
A61K 31/4184
. . . . .
condensed with carbocyclic rings, e.g. benzimidazoles [2013-01]
A61K 31/4188
. . . . .
condensed with other heterocyclic ring systems, e.g. biotin, sorbinil [2013-01]
A61K 31/4192
. . . .
1,2,3-Triazoles [2013-01]
A61K 31/4196
. . . .
1,2,4-Triazoles [2013-01]
A61K 31/42
. . . .
Oxazoles [2013-01]
A61K 31/421
. . . . .
1,3-Oxazoles, e.g. pemoline, trimethadione [2013-01]
A61K 31/422
. . . . .
not condensed and containing further heterocyclic rings [2013-01]
A61K 31/423
. . . . .
condensed with carbocyclic rings [2013-01]
A61K 31/424
. . . . .
condensed with heterocyclic ring systems, e.g. clavulanic acid [2013-01]
A61K 31/4245
. . . .
Oxadiazoles [2013-01]
A61K 31/425
. . . .
Thiazoles [2013-01]
A61K 31/426
. . . . .
1,3-Thiazoles [2013-01]
A61K 31/427
. . . . .
not condensed and containing further heterocyclic rings [2013-01]
A61K 31/428
. . . . .
condensed with carbocyclic rings [2013-01]
A61K 31/429
. . . . .
condensed with heterocyclic ring systems [2013-01]
A61K 31/43
. . . . . .
Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula Image, e.g. penicillins, penems [2016-08]
A61K 31/431
. . . . . . .
containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin [2013-01]
A61K 31/433
. . . .
Thidiazoles [2013-01]
A61K 31/435
. . .
having six-membered rings with one nitrogen as the only ring hetero atom [2013-01]
A61K 31/4353
. . . .
ortho- or peri-condensed with heterocyclic ring systems [2013-01]
A61K 31/4355
. . . . .
the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom [2013-01]
A61K 31/436
. . . . .
the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin [2016-11]
A61K 31/4365
. . . . .
the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine [2013-01]
A61K 31/437
. . . . .
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline [2013-01]
A61K 31/4375
. . . . .
the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine [2013-01]
A61K 31/438
. . . .
The ring being spiro-condensed with carbocyclic or heterocyclic ring systems [2019-05]
A61K 31/439
. . . .
the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K 31/46) [2013-01]
A61K 31/44
. . . .
Non condensed pyridines; Hydrogenated derivatives thereof [2013-01]
A61K 31/4402
. . . . .
only substituted in position 2, e.g. pheniramine, bisacodyl [2013-01]
A61K 31/4406
. . . . .
only substituted in position 3, e.g. zimeldine (nicotinic acid A61K 31/455) [2013-01]
A61K 31/4409
. . . . .
only substituted in position 4, e.g. isoniazid, iproniazid [2013-01]
A61K 31/4412
. . . . .
having oxo groups directly attached to the heterocyclic ring [2013-01]
A61K 31/4415
. . . . .
Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K 31/675) [2013-01]
A61K 31/4418
. . . . .
having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine [2013-01]
A61K 31/4422
. . . . .
1,4-Dihydropyridines, e.g. nifedipine, nicardipine [2013-01]
A61K 31/4425
. . . . .
Pyridinium derivatives, e.g. pralidoxime, pyridostigmine [2013-01]
A61K 31/4427
. . . . .
containing further heterocyclic ring systems [2013-01]
A61K 31/443
. . . . . .
containing a five-membered ring with oxygen as a ring hetero atom [2013-01]
A61K 31/4433
. . . . . .
containing a six-membered ring with oxygen as a ring hetero atom [2013-01]
A61K 31/4436
. . . . . .
containing a heterocyclic ring having sulfur as a ring hetero atom [2013-01]
A61K 31/4439
. . . . . .
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K 31/465) [2013-01]
A61K 31/444
. . . . . .
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone [2013-01]
A61K 31/445
. . . . .
Non condensed piperidines, e.g. piperocaine [2013-01]
A61K 31/4453
. . . . . .
only substituted in position 1, e.g. propipocaine, diperodon [2013-01]
A61K 31/4458
. . . . . .
only substituted in position 2, e.g. methylphenidate [2013-01]
A61K 31/4462
. . . . . .
only substituted in position 3 [2013-01]
A61K 31/4465
. . . . . .
only substituted in position 4 [2013-01]
A61K 31/4468
. . . . . .
having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl [2013-01]
A61K 31/45
. . . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide [2013-01]
A61K 31/451
. . . . . .
having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine [2013-01]
A61K 31/4515
. . . . . .
having a butyrophenone group in position 1, e.g. haloperidol (pipamperone A61K 31/4545) [2013-01]
A61K 31/452
. . . . . .
Piperidinium derivatives (pancuronium A61K 31/58) [2013-01]
A61K 31/4523
. . . . . .
containing further heterocyclic ring systems [2013-01]
A61K 31/4525
. . . . . . .
containing a five-membered ring with oxygen as a ring hetero atom [2013-01]
A61K 31/453
. . . . . . .
containing a six-membered ring with oxygen as a ring hetero atom [2013-01]
A61K 31/4535
. . . . . . .
containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen [2013-01]
A61K 31/454
. . . . . . .
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone [2013-01]
A61K 31/4545
. . . . . . .
containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine [2013-01]
A61K 31/455
. . . . .
Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides [2013-01]
A61K 31/46
. . . .
8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine [2013-01]
A61K 31/465
. . . .
Nicotine; Derivatives thereof [2013-01]
A61K 31/47
. . . .
Quinolines; Isoquinolines [2013-01]
A61K 31/4704
. . . . .
2-Quinolinones, e.g. carbostyril [2013-01]
A61K 31/4706
. . . . .
4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine [2013-01]
A61K 31/4709
. . . . .
Non-condensed quinolines and containing further heterocyclic rings [2013-01]
A61K 31/472
. . . . .
Non-condensed isoquinolines, e.g. papaverine [2013-01]
A61K 31/4725
. . . . . .
containing further heterocyclic rings [2013-01]
A61K 31/473
. . . . .
ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines [2013-01]
A61K 31/4738
. . . . .
ortho- or peri-condensed with heterocyclic ring systems [2013-01]
A61K 31/4741
. . . . . .
condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline [2013-01]
A61K 31/4743
. . . . . .
condensed with ring systems having sulfur as a ring hetero atom [2013-01]
A61K 31/4745
. . . . . .
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K 31/475; ergoline derivatives A61K 31/48) [2013-01]
A61K 31/4747
. . . . .
spiro-condensed [2017-08]
A61K 31/4748
. . . . .
forming part of bridged ring systems (strychnine A61K 31/475; morphinan derivatives A61K 31/485) [2013-01]
A61K 31/475
. . . . .
having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K 31/4375) [2013-01]
A61K 31/48
. . . . .
Ergoline derivatives, e.g. lysergic acid, ergotamine [2013-01]
A61K 31/485
. . . . .
Morphinan derivatives, e.g. morphine, codeine [2013-01]
A61K 31/49
. . . . .
Cinchonan derivatives, e.g. quinine [2013-01]
A61K 31/495
. . .
having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K 31/48 takes precedence {; with three nitrogen atoms A61K 31/53}) [2013-01]
A61K 31/496
. . . .
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin [2024-01]
A61K 31/4965
. . . .
Non-condensed pyrazines [2013-01]
A61K 31/497
. . . . .
containing further heterocyclic rings [2013-01]
A61K 31/498
. . . .
Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine [2013-01]
A61K 31/4985
. . . .
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems [2013-01]
A61K 31/499
. . . .
Spiro-condensed pyrazines or piperazines [2013-01]
A61K 31/4995
. . . .
Pyrazines or piperazines forming part of bridged ring systems [2013-01]
A61K 31/50
. . . .
Pyridazines; Hydrogenated pyridazines [2013-01]
A61K 31/501
. . . . .
not condensed and containing further heterocyclic rings [2013-01]
A61K 31/502
. . . . .
ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine [2013-01]
A61K 31/5025
. . . . .
ortho- or peri-condensed with heterocyclic ring systems [2013-01]
A61K 31/503
. . . . .
spiro-condensed [2013-01]
A61K 31/504
. . . . .
forming part of bridged ring systems [2013-01]
A61K 31/505
. . . .
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim [2013-01]
A61K 31/506
. . . . .
not condensed and containing further heterocyclic rings [2013-01]
A61K 31/51
. . . . . .
Thiamines, e.g. vitamin B1 [2013-01]
A61K 31/513
. . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. cytosine [2013-01]
A61K 31/515
. . . . . .
Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital [2014-02]
A61K 31/517
. . . . .
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine [2013-01]
A61K 31/519
. . . . .
ortho- or peri-condensed with heterocyclic rings [2013-01]
A61K 31/52
. . . . . .
Purines, e.g. adenine [2013-01]
A61K 31/522
. . . . . . .
having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir [2013-01]
A61K 31/525
. . . . . .
Isoalloxazines, e.g. riboflavins, vitamin B2 [2013-01]
A61K 31/527
. . . . .
spiro-condensed [2013-01]
A61K 31/529
. . . . .
forming part of bridged ring systems [2013-01]
A61K 31/53
. . .
having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K 31/555 {; with four nitrogen atoms A61K 31/495}) [2013-01]
A61K 31/535
. . .
having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines [2013-01]
A61K 31/5355
. . . .
Non-condensed oxazines and containing further heterocyclic rings [2017-08]
A61K 31/536
. . . .
ortho- or peri-condensed with carbocyclic ring systems [2013-01]
A61K 31/5365
. . . .
ortho- or peri-condensed with heterocyclic ring systems [2013-01]
A61K 31/537
. . . .
spiro-condensed or forming part of bridged ring systems [2013-01]
A61K 31/5375
. . . .
1,4-Oxazines, e.g. morpholine [2013-01]
A61K 31/5377
. . . . .
not condensed and containing further heterocyclic rings, e.g. timolol [2013-01]
A61K 31/538
. . . . .
ortho- or peri-condensed with carbocyclic ring systems [2013-01]
A61K 31/5383
. . . . .
ortho- or peri-condensed with heterocyclic ring systems [2013-01]
A61K 31/5386
. . . . .
spiro-condensed or forming part of bridged ring systems [2017-08]
A61K 31/539
. . . .
having two or more oxygen atoms in the same ring, e.g. dioxazines [2013-01]
A61K 31/5395
. . . .
having two or more nitrogen atoms in the same ring, e.g. oxadiazines [2013-01]
A61K 31/54
. . .
having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame [2013-01]
A61K 31/541
. . . .
Non-condensed thiazines containing further heterocyclic rings [2017-08]
A61K 31/5415
. . . .
ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam [2013-01]
A61K 31/542
. . . .
ortho- or peri-condensed with heterocyclic ring systems [2013-01]
A61K 31/545
. . . . .
Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: Image , e.g. cephalosporins, {cefaclor, or cephalexine} [2013-01]
A61K 31/546
. . . . . .
containing further heterocyclic rings, e.g. cephalothin [2013-01]
A61K 31/547
. . . .
spiro-condensed or forming part of bridged ring systems [2013-01]
A61K 31/548
. . . .
having two or more sulfur atoms in the same ring [2013-01]
A61K 31/549
. . . .
having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide [2013-01]
A61K 31/55
. . .
having seven-membered rings, e.g. azelastine, pentylenetetrazole [2013-01]
A61K 31/551
. . . .
having two nitrogen atoms, e.g. dilazep [2013-01]
A61K 31/5513
. . . . .
1,4-Benzodiazepines, e.g. diazepam {or clozapine} [2013-01]
A61K 31/5517
. . . . . .
condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam [2013-01]
A61K 31/553
. . . .
having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine [2013-01]
A61K 31/554
. . . .
having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem [2022-01]
​
A61K 31/5545
. . .
{having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings} [2022-01]
NOTE

  • {This subgroup does not cover N-containing eight-membered rings which also contain additional condensed and non-condensed nitrogen containing 3-7 membered rings, which are covered by subgroups A61K 31/396 - A61K 31/554.}
A61K 31/555
. .
containing heavy metals, e.g. hemin, hematin, melarsoprol [2013-01]
A61K 31/557
.
Eicosanoids, e.g. leukotrienes {or prostaglandins} [2013-01]
A61K 31/5575
. .
having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha [2017-08]
A61K 31/5578
. .
having a pentalene ring system, e.g. carbacyclin, iloprost [2013-01]
A61K 31/558
. .
having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes [2013-01]
A61K 31/5585
. . .
having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin [2013-01]
A61K 31/559
. .
having heterocyclic rings containing hetero atoms other than oxygen [2013-01]
​
A61K 31/56
.
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids [2021-02]
NOTE

  • Attention is drawn to Note (1) following the title of subclass C07J which explains what is covered by the term "steroids"
A61K 31/565
. .
not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol [2013-01]
A61K 31/566
. . .
having an oxo group in position 17, e.g. estrone [2013-01]
A61K 31/567
. . .
substituted in position 17 alpha, e.g. mestranol, norethandrolone [2013-01]
A61K 31/568
. . .
substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone [2013-01]
A61K 31/5685
. . . .
having an oxo group in position 17, e.g. androsterone [2013-01]
A61K 31/569
. . . .
substituted in position 17 alpha, e.g. ethisterone [2013-01]
A61K 31/57
. .
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone [2021-02]
A61K 31/573
. . .
substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone [2021-02]
A61K 31/575
. .
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol [2013-01]
A61K 31/58
. .
containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K 31/7048}) [2021-02]
A61K 31/585
. . .
containing lactone rings, e.g. oxandrolone, bufalin [2013-01]
A61K 31/59
.
Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems [2013-01]
A61K 31/592
. .
9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2 [2013-01]
A61K 31/593
. .
9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3 [2013-01]
A61K 31/60
.
Salicylic acid; Derivatives thereof [2013-01]
A61K 31/603
. .
having further aromatic rings, e.g. diflunisal [2013-01]
A61K 31/606
. .
having amino groups [2013-01]
A61K 31/609
. .
Amides, e.g. salicylamide {(labetalol, metoclopramide A61K 31/166)} [2013-01]
A61K 31/612
. .
having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid (fosfosal A61K 31/661) [2013-01]
A61K 31/616
. . .
by carboxylic acids, e.g. acetylsalicylic acid [2017-08]
A61K 31/618
. .
having the carboxyl group in position 1 esterified, e.g. salsalate [2013-01]
A61K 31/621
. . .
having the hydroxy group in position 2 esterified, e.g. benorylate [2013-01]
A61K 31/625
. .
having heterocyclic substituents, e.g. 4-salicycloylmorpholine, (sulfasalazine A61K 31/635) [2013-01]
A61K 31/63
.
Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide [2013-01]
A61K 31/635
. .
having a heterocyclic ring, e.g. sulfadiazine [2020-08]
A61K 31/64
.
Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide [2013-01]
A61K 31/65
.
Tetracyclines [2013-01]
A61K 31/655
.
Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds [2017-08]
​
A61K 31/658
.
{o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol} [2023-05]
WARNING

A61K 31/66
.
Phosphorus compounds [2013-01]
A61K 31/661
. .
Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos} [2017-08]
A61K 31/6615
. . .
Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid [2013-01]
A61K 31/662
. .
Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon [2017-08]
A61K 31/663
. . .
Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid [2013-01]
A61K 31/664
. .
Amides of phosphorus acids [2013-01]
A61K 31/665
. .
having oxygen as a ring hetero atom, e.g. fosfomycin [2013-01]
A61K 31/67
. .
having sulfur as a ring hetero atom [2013-01]
A61K 31/675
. .
having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate [2013-01]
A61K 31/683
. .
Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols [2013-01]
A61K 31/685
. . .
one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin [2013-01]
A61K 31/688
. . .
both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins [2017-08]
A61K 31/69
.
Boron compounds [2013-01]
A61K 31/695
.
Silicon compounds [2013-01]
​
A61K 31/70
.
Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K 31/047) [2013-01]
NOTE

  • In this group, the expressions are used with the meanings indicated in Note (3) following the title of the subclass C07H
A61K 31/7004
. .
Monosaccharides having only carbon, hydrogen and oxygen atoms [2017-08]
A61K 31/7008
. .
Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine [2013-01]
A61K 31/7012
. .
Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K 31/191; ascorbic acid A61K 31/375) [2013-01]
A61K 31/7016
. .
Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K 31/7032) [2013-01]
A61K 31/702
. .
Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages [2013-01]
A61K 31/7024
. .
Esters of saccharides [2013-01]
A61K 31/7028
. .
Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages [2013-01]
A61K 31/7032
. . .
attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides [2017-08]
A61K 31/7034
. . .
attached to a carbocyclic compound, e.g. phloridzin [2013-01]
A61K 31/7036
. . . .
having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins [2013-01]
A61K 31/704
. . . .
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K 31/7048)} [2013-01]
A61K 31/7042
. .
Compounds having saccharide radicals and heterocyclic rings [2013-01]
A61K 31/7048
. . .
having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} [2021-02]
A61K 31/7052
. . .
having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides [2013-01]
A61K 31/7056
. . . .
containing five-membered rings with nitrogen as a ring hetero atom [2013-01]
A61K 31/706
. . . .
containing six-membered rings with nitrogen as a ring hetero atom [2013-01]
A61K 31/7064
. . . . .
containing condensed or non-condensed pyrimidines [2013-01]
A61K 31/7068
. . . . . .
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid [2013-01]
A61K 31/7072
. . . . . . .
having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine [2013-01]
A61K 31/7076
. . . . . .
containing purines, e.g. adenosine, adenylic acid [2013-01]
A61K 31/708
. . . . . . .
having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid [2013-01]
A61K 31/7084
. .
Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide [2013-01]
A61K 31/7088
. .
Compounds having three or more nucleosides or nucleotides [2013-01]
A61K 31/7105
. . .
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links [2013-01]
A61K 31/711
. . .
Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links [2013-01]
A61K 31/7115
. . .
Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine [2013-01]
A61K 31/712
. . .
Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose [2013-01]
A61K 31/7125
. . .
Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters [2013-01]
A61K 31/713
. . .
Double-stranded nucleic acids or oligonucleotides [2013-01]
A61K 31/7135
. .
Compounds containing heavy metals [2013-01]
A61K 31/714
. . .
Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12 [2013-01]
A61K 31/715
. .
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters [2013-01]
A61K 31/716
. . .
Glucans [2013-01]
A61K 31/717
. . . .
Celluloses [2013-01]
A61K 31/718
. . . .
Starch or degraded starch, e.g. amylose, amylopectin [2013-01]
A61K 31/719
. . . .
Pullulans [2013-01]
A61K 31/721
. . . .
Dextrans [2013-01]
A61K 31/722
. . . .
Chitin, chitosan [2013-01]
A61K 31/723
. . . .
Xanthans [2013-01]
A61K 31/724
. . . .
Cyclodextrins [2013-01]
A61K 31/726
. . .
Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K 31/737) [2013-01]
A61K 31/727
. . . .
Heparin; Heparan [2013-01]
A61K 31/728
. . . .
Hyaluronic acid [2013-01]
A61K 31/729
. . .
Agar; Agarose; Agaropectin [2013-01]
A61K 31/731
. . .
Carrageenans [2013-01]
A61K 31/732
. . .
Pectin [2013-01]
A61K 31/733
. . .
Fructosans, e.g. inulin [2013-01]
A61K 31/734
. . .
Alginic acid [2013-01]
A61K 31/736
. . .
Glucomannans or galactomannans, e.g. locust bean gum, guar gum [2013-01]
A61K 31/737
. . .
Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K 31/727 takes precedence) [2013-01]
A61K 31/738
. . .
Cross-linked polysaccharides [2013-01]
A61K 31/739
. . .
Lipopolysaccharides [2013-01]
A61K 31/74
.
Synthetic polymeric materials [2013-01]
A61K 31/745
. .
Polymers of hydrocarbons [2013-01]
A61K 31/75
. . .
of ethene [2013-01]
A61K 31/755
. .
Polymers containing halogen [2013-01]
A61K 31/76
. . .
of vinyl chloride [2013-01]
A61K 31/765
. .
Polymers containing oxygen [2013-01]
A61K 31/77
. . .
of oxiranes [2013-01]
A61K 31/775
. . .
Phenolic resins [2013-01]
A61K 31/78
. . .
of acrylic acid or derivatives thereof [2013-01]
A61K 31/785
. .
Polymers containing nitrogen [2013-01]
A61K 31/787
. . .
containing heterocyclic rings having nitrogen as a ring hetero atom [2013-01]
A61K 31/79
. . . .
Polymers of vinyl pyrrolidone [2013-01]
A61K 31/795
. .
Polymers containing sulfur [2013-01]
A61K 31/80
. .
Polymers containing hetero atoms not provided for in groups A61K 31/755 - A61K 31/795 [2016-05]
A61K 33/00
Medicinal preparations containing inorganic active ingredients [2013-01]
A61K 33/02
.
Ammonia; Compounds thereof [2013-01]
A61K 33/04
.
Sulfur, selenium or tellurium; Compounds thereof [2013-01]
A61K 33/06
.
Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} [2017-08]
A61K 33/08
. .
Oxides; Hydroxides [2013-01]
A61K 33/10
. .
Carbonates; Bicarbonates [2013-01]
A61K 33/12
. .
Magnesium silicate [2013-01]
A61K 33/14
.
Alkali metal chlorides; Alkaline earth metal chlorides [2013-01]
A61K 33/16
.
Fluorine compounds [2013-01]
A61K 33/18
.
Iodine; Compounds thereof [2013-01]
A61K 33/20
.
Elemental chlorine; Inorganic compounds releasing chlorine [2013-01]
A61K 33/22
.
Boron compounds [2013-01]
A61K 33/24
.
Heavy metals; Compounds thereof [2022-01]
A61K 33/241
. .
Lead; Compounds thereof [2022-01]
A61K 33/242
. .
Gold; Compounds thereof [2022-01]
A61K 33/243
. .
Platinum; Compounds thereof [2022-01]
A61K 33/244
. .
Lanthanides; Compounds thereof (medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K 51/00) [2022-01]
A61K 33/245
. .
Bismuth; Compounds thereof [2019-01]
A61K 33/26
. .
Iron; Compounds thereof [2013-01]
A61K 33/28
. .
Mercury; Compounds thereof [2013-01]
A61K 33/30
. .
Zinc; Compounds thereof [2013-01]
A61K 33/32
. .
Manganese; Compounds thereof [2013-01]
A61K 33/34
. .
Copper; Compounds thereof [2013-01]
A61K 33/36
. .
Arsenic; Compounds thereof [2013-01]
A61K 33/38
. .
Silver; Compounds thereof [2013-01]
A61K 33/40
.
Peroxides [2013-01]
A61K 33/42
.
Phosphorus; Compounds thereof [2013-01]
A61K 33/44
.
Elemental carbon, e.g. charcoal, carbon black [2013-01]
​
A61K 35/00
Medicinal preparations containing materials or reaction products thereof with undetermined constitution [2015-01]
NOTES

  • In this group, classification is made for each active component or material. For each active component or material, classification is then made in the last appropriate place.
  • When classifying in this group, classification is also made in group B01D 15/08 insofar as subject matter of general interest relating to chromatography is concerned.
A61K 35/02
.
from inanimate materials (carbon A61K 33/44) [2015-01]
A61K 35/04
. .
Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate [2015-01]
A61K 35/06
. . .
Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons [2015-01]
A61K 35/08
. .
Mineral waters; Sea water [2015-01]
A61K 35/10
. .
Peat; Amber; Turf; Humus [2015-01]
A61K 2035/11
.
{Medicinal preparations comprising living procariotic cells} [2013-01]
A61K 2035/115
. .
{Probiotics} [2013-01]
​
A61K 35/12
.
Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K 39/00) [2020-01]
NOTE

  • If the cells are characterised, classification is made in the group covering the corresponding tissue or tissue of origin.
A61K 2035/122
. .
{for inducing tolerance or supression of immune responses} [2013-01]
A61K 2035/124
. .
{the cells being hematopoietic, bone marrow derived or blood cells} [2013-01]
A61K 2035/126
. .
{Immunoprotecting barriers, e.g. jackets, diffusion chambers} [2013-01]
A61K 2035/128
. . .
{capsules, e.g. microcapsules} [2013-01]
A61K 35/13
. .
Tumour cells, irrespective of tissue of origin (tumour vaccines A61K 39/00) [2015-01]
A61K 35/14
. .
Blood; Artificial blood (perfluorocarbons A61K 31/02; umbilical cord blood A61K 35/51; haemoglobin A61K 38/42) [2015-01]
​
A61K 35/15
. . .
Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K 39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K 39/00) [2023-05]
WARNING

A61K 35/16
. . .
Blood plasma; Blood serum (umbilical cord blood A61K 35/51) [2015-01]
​
A61K 35/17
. . .
Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K 39/00) [2023-05]
WARNING

A61K 35/18
. . .
Erythrocytes (haemoglobin A61K 38/42) [2015-01]
A61K 35/19
. . .
Platelets; Megacaryocytes [2015-01]
A61K 35/20
. .
Milk; Whey; Colostrum [2015-01]
A61K 35/22
. .
Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland [2015-01]
A61K 35/24
. .
Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid (saliva A61K 35/38) [2015-01]
A61K 35/26
. .
Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes [2015-01]
A61K 35/28
. .
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells [2015-01]
A61K 35/30
. .
Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue [2015-01]
A61K 35/32
. .
Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane [2015-01]
A61K 35/33
. .
Fibroblasts [2015-01]
A61K 35/34
. .
Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K 35/44) [2015-01]
A61K 35/35
. .
Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K 35/28; collagen A61K 38/39) [2015-01]
A61K 35/36
. .
Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K 35/39) [2015-01]
A61K 35/37
. .
Digestive system [2013-01]
A61K 35/38
. . .
Stomach; Intestine; Goblet cells; Oral mucosa; Saliva [2015-01]
A61K 35/39
. . .
Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K 35/36) [2015-01]
A61K 35/407
. . .
Liver; Hepatocytes [2015-01]
A61K 35/413
. . .
Gall bladder; Bile [2015-01]
A61K 35/42
. .
Respiratory system, e.g. lungs, bronchi or lung cells [2015-01]
A61K 35/44
. .
Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells [2015-01]
A61K 35/48
. .
Reproductive organs [2013-01]
A61K 35/50
. . .
Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells [2015-01]
A61K 35/51
. . .
Umbilical cord; Umbilical cord blood; Umbilical stem cells [2015-01]
A61K 35/52
. . .
Sperm; Prostate; Seminal fluid; Leydig cells of testes [2015-01]
A61K 35/54
. . .
Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells [2015-01]
A61K 35/545
. . . .
Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells [2015-01]
A61K 35/55
. .
Glands not provided for in groups A61K 35/22 - A61K 35/545, e.g. thyroids, parathyroids or pineal glands [2015-01]
A61K 35/56
.
Materials from animals other than mammals [2016-05]
A61K 35/57
. .
Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli [2015-01]
A61K 35/58
. .
Reptiles (antigens from snakes A61K 39/38) [2015-01]
A61K 35/583
. . .
Snakes; Lizards, e.g. chameleons (therapeutic use of a snake venom protein A61K 38/00) [2015-01]
A61K 35/586
. . .
Turtles; Tortoises, e.g. terrapins [2015-01]
A61K 35/60
. .
Fish, e.g. seahorses; Fish eggs [2015-01]
A61K 35/612
. .
Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles [2015-01]
A61K 35/614
. .
Cnidaria, e.g. sea anemones, corals, coral animals or jellyfish [2015-01]
A61K 35/616
. .
Echinodermata, e.g. starfish, sea cucumbers or sea urchins [2015-01]
A61K 35/618
. .
Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs [2015-01]
A61K 35/62
. .
Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia [2015-01]
A61K 35/63
. .
Arthropods (aquatic crustaceans A61K 35/612) [2015-01]
A61K 35/64
. . .
Insects, e.g. bees, wasps or fleas [2015-01]
A61K 35/644
. . . .
Beeswax; Propolis; Royal jelly; Honey [2015-01]
A61K 35/646
. . .
Arachnids, e.g. spiders, scorpions, ticks or mites [2015-01]
A61K 35/648
. . .
Myriapods, e.g. centipedes or millipedes [2015-01]
A61K 35/65
. .
Amphibians, e.g. toads, frogs, salamanders or newts [2015-01]
A61K 35/655
. .
Aquatic animals other than those covered by groups A61K 35/57 - A61K 35/65 [2015-01]
A61K 35/66
.
Microorganisms or materials therefrom (fungi, yeasts or candida A61K 36/06) [2017-08]
A61K 35/68
. .
Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma [2015-01]
A61K 35/74
. .
Bacteria (therapeutic use of a bacterial protein A61K 38/00) [2015-01]
A61K 35/741
. . .
Probiotics (probiotic yeast, e.g. saccharomyces A61K 36/06) [2015-01]
A61K 35/742
. . . .
Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes [2015-01]
A61K 35/744
. . . .
Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs [2015-01]
A61K 35/745
. . . . .
Bifidobacteria [2015-01]
A61K 35/747
. . . . .
Lactobacilli, e.g. L. acidophilus or L. brevis [2015-01]
A61K 35/748
. . .
Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina (algae, microalgae or microphytes A61K 36/02) [2015-01]
A61K 35/76
. .
Viruses; Subviral particles; Bacteriophages [2015-01]
A61K 35/761
. . .
Adenovirus [2015-01]
A61K 35/763
. . .
Herpes virus [2015-01]
A61K 35/765
. . .
Reovirus; Rotavirus [2015-01]
A61K 35/766
. . .
Rhabdovirus, e.g. vesicular stomatitis virus [2015-01]
A61K 35/768
. . .
Oncolytic viruses not provided for in groups A61K 35/761 - A61K 35/766 [2015-01]
​
A61K 36/00
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines {(antigens from pollen A61K 39/36)} [2013-01]
NOTE

  • In this group, common names of plants, where given, are presented in brackets following their corresponding Latin names.
A61K 36/02
.
Algae [2013-01]
A61K 36/03
. .
Phaeophycota or phaeophyta (brown algae), e.g. Fucus [2013-01]
A61K 36/04
. .
Rhodophycota or rhodophyta (red algae), e.g. Porphyra [2017-08]
A61K 36/05
. .
Chlorophycota or chlorophyta (green algae), e.g. Chlorella [2013-01]
A61K 36/06
.
Fungi, e.g. yeasts [2013-01]
A61K 36/062
. .
Ascomycota [2013-01]
A61K 36/064
. . .
Saccharomycetales, e.g. baker's yeast [2013-01]
A61K 36/066
. . .
Clavicipitaceae [2013-01]
A61K 36/068
. . . .
Cordyceps [2013-01]
​
A61K 36/07
. .
Basidiomycota, e.g. Cryptococcus [2024-05]
WARNING

​
A61K 36/071
. . .
{Agaricus} [2024-05]
WARNING

A61K 36/074
. . .
Ganoderma [2013-01]
A61K 36/076
. . .
Poria [2013-01]
​
A61K 36/078
. . .
{Psilocybe} [2024-05]
WARNING

A61K 36/09
.
Lichens [2013-01]
A61K 36/10
.
Bryophyta (mosses) [2024-05]
A61K 36/11
.
Pteridophyta or Filicophyta (ferns) [2013-01]
A61K 36/12
. .
Filicopsida or Pteridopsida [2013-01]
A61K 36/126
. . .
Drynaria [2013-01]
A61K 36/13
.
Coniferophyta (gymnosperms) [2013-01]
A61K 36/14
. .
Cupressaceae (Cypress family), e.g. juniper or cypress [2013-01]
A61K 36/15
. .
Pinaceae (Pine family), e.g. pine or cedar [2013-01]
A61K 36/16
.
Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family) [2013-01]
A61K 36/17
.
Gnetophyta, e.g. Ephedraceae (Mormon-tea family) [2017-08]
​
A61K 36/18
.
Magnoliophyta (angiosperms) [2024-05]
WARNING

​
A61K 36/185
. .
Magnoliopsida (dicotyledons) [2024-05]
WARNING

A61K 36/19
. . .
Acanthaceae (Acanthus family) [2013-01]
A61K 36/195
. . . .
Strobilanthes [2013-01]
A61K 36/20
. . .
Aceraceae (Maple family) [2013-01]
A61K 36/21
. . .
Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth [2013-01]
A61K 36/22
. . .
Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak [2013-01]
A61K 36/23
. . .
Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin [2013-01]
A61K 36/232
. . . .
Angelica [2013-01]
A61K 36/233
. . . .
Bupleurum [2013-01]
A61K 36/234
. . . .
Cnidium (snowparsley) [2013-01]
A61K 36/235
. . . .
Foeniculum (fennel) [2013-01]
A61K 36/236
. . . .
Ligusticum (licorice-root) [2013-01]
A61K 36/237
. . . .
Notopterygium [2013-01]
A61K 36/238
. . . .
Saposhnikovia [2013-01]
A61K 36/24
. . .
Apocynaceae (Dogbane family), e.g. plumeria or periwinkle [2013-01]
A61K 36/25
. . .
Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax [2013-01]
A61K 36/254
. . . .
Acanthopanax or Eleutherococcus [2013-01]
A61K 36/258
. . . .
Panax (ginseng) [2013-01]
A61K 36/26
. . .
Aristolochiaceae (Birthwort family), e.g. heartleaf [2013-01]
A61K 36/264
. . . .
Aristolochia (Dutchman's pipe) [2013-01]
A61K 36/268
. . . .
Asarum (wild ginger) [2013-01]
A61K 36/27
. . .
Asclepiadaceae (Milkweed family), e.g. hoya [2013-01]
A61K 36/28
. . .
Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea [2013-01]
A61K 36/282
. . . .
Artemisia, e.g. wormwood or sagebrush [2013-01]
A61K 36/284
. . . .
Atractylodes [2013-01]
A61K 36/285
. . . .
Aucklandia [2013-01]
A61K 36/286
. . . .
Carthamus (distaff thistle) [2013-01]
A61K 36/287
. . . .
Chrysanthemum, e.g. daisy [2013-01]
A61K 36/288
. . . .
Taraxacum (dandelion) [2013-01]
A61K 36/289
. . . .
Vladimiria [2013-01]
A61K 36/29
. . .
Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple [2013-01]
A61K 36/296
. . . .
Epimedium [2013-01]
A61K 36/30
. . .
Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not [2013-01]
A61K 36/31
. . .
Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi [2013-01]
A61K 36/315
. . . .
Isatis, e.g. Dyer's woad [2013-01]
A61K 36/32
. . .
Burseraceae (Frankincense family) [2013-01]
A61K 36/324
. . . .
Boswellia, e.g. frankincense [2013-01]
A61K 36/328
. . . .
Commiphora, e.g. mecca myrrh or balm of Gilead [2013-01]
A61K 36/33
. . .
Cactaceae (Cactus family), e.g. pricklypear or Cereus [2013-01]
A61K 36/34
. . .
Campanulaceae (Bellflower family) [2013-01]
A61K 36/342
. . . .
Adenophora [2013-01]
A61K 36/344
. . . .
Codonopsis [2013-01]
A61K 36/346
. . . .
Platycodon [2013-01]
​
A61K 36/348
. . .
{Cannabaceae} [2024-05]
WARNING

A61K 36/3482
. . . .
{Cannabis} [2024-05]
A61K 36/3486
. . . .
{Humulus} [2024-05]
A61K 36/35
. . .
Caprifoliaceae (Honeysuckle family) [2013-01]
A61K 36/355
. . . .
Lonicera (honeysuckle) [2013-01]
A61K 36/36
. . .
Caryophyllaceae (Pink family), e.g. babysbreath or soapwort [2013-01]
A61K 36/37
. . .
Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree [2013-01]
A61K 36/38
. . .
Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort [2013-01]
A61K 36/39
. . .
Convolvulaceae (Morning-glory family), e.g. bindweed [2013-01]
A61K 36/40
. . .
Cornaceae (Dogwood family) [2013-01]
A61K 36/41
. . .
Crassulaceae (Stonecrop family) [2013-01]
A61K 36/42
. . .
Cucurbitaceae (Cucumber family) [2013-01]
A61K 36/424
. . . .
Gynostemma [2013-01]
A61K 36/428
. . . .
Trichosanthes [2013-01]
A61K 36/43
. . .
Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder [2013-01]
A61K 36/44
. . .
Ebenaceae (Ebony family), e.g. persimmon [2013-01]
A61K 36/45
. . .
Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry [2013-01]
A61K 36/46
. . .
Eucommiaceae (Eucommia family), e.g. hardy rubber tree [2013-01]
A61K 36/47
. . .
Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean) [2013-01]
A61K 36/48
. . .
Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae [2013-01]
A61K 36/481
. . . .
Astragalus (milkvetch) [2013-01]
A61K 36/482
. . . .
Cassia, e.g. golden shower tree [2013-01]
A61K 36/483
. . . .
Gleditsia (locust) [2013-01]
A61K 36/484
. . . .
Glycyrrhiza (licorice) [2013-01]
A61K 36/485
. . . .
Gueldenstaedtia [2013-01]
A61K 36/486
. . . .
Millettia [2013-01]
A61K 36/487
. . . .
Psoralea [2013-01]
A61K 36/488
. . . .
Pueraria (kudzu) [2013-01]
A61K 36/489
. . . .
Sophora, e.g. necklacepod or mamani [2013-01]
A61K 36/49
. . .
Fagaceae (Beech family), e.g. oak or chestnut [2013-01]
A61K 36/50
. . .
Fumariaceae (Fumitory family), e.g. bleeding heart [2013-01]
A61K 36/505
. . . .
Corydalis [2013-01]
A61K 36/51
. . .
Gentianaceae (Gentian family) [2013-01]
A61K 36/515
. . . .
Gentiana [2013-01]
A61K 36/52
. . .
Juglandaceae (Walnut family) [2013-01]
A61K 36/53
. . .
Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender [2013-01]
A61K 36/532
. . . .
Agastache, e.g. giant hyssop [2013-01]
A61K 36/533
. . . .
Leonurus (motherwort) [2013-01]
A61K 36/534
. . . .
Mentha (mint) [2013-01]
A61K 36/535
. . . .
Perilla (beefsteak plant) [2013-01]
A61K 36/536
. . . .
Prunella or Brunella (selfheal) [2013-01]
A61K 36/537
. . . .
Salvia (sage) [2013-01]
A61K 36/538
. . . .
Schizonepeta [2013-01]
A61K 36/539
. . . .
Scutellaria (skullcap) [2013-01]
A61K 36/54
. . .
Lauraceae (Laurel family), e.g. cinnamon or sassafras [2013-01]
A61K 36/55
. . .
Linaceae (Flax family), e.g. Linum [2013-01]
A61K 36/56
. . .
Loganiaceae (Logania family), e.g. trumpetflower or pinkroot [2013-01]
A61K 36/57
. . .
Magnoliaceae (Magnolia family) [2013-01]
A61K 36/575
. . . .
Magnolia [2013-01]
​
A61K 36/577
. . .
{Malvaceae (Mallow family)} [2024-05]
WARNING

A61K 36/5775
. . . .
{Hibiscus} [2024-05]
A61K 36/5777
. . . .
{Theobroma, e.g. cocao or cocoa} [2024-05]
A61K 36/58
. . .
Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem) [2013-01]
A61K 36/59
. . .
Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead [2013-01]
A61K 36/60
. . .
Moraceae (Mulberry family), e.g. breadfruit or fig [2013-01]
A61K 36/605
. . . .
Morus (mulberry) [2013-01]
A61K 36/61
. . .
Myrtaceae (Myrtle family), e.g. teatree or eucalyptus [2013-01]
A61K 36/62
. . .
Nymphaeaceae (Water-lily family) [2013-01]
A61K 36/63
. . .
Oleaceae (Olive family), e.g. jasmine, lilac or ash tree [2013-01]
A61K 36/634
. . . .
Forsythia [2013-01]
A61K 36/638
. . . .
Ligustrum, e.g. Chinese privet [2013-01]
A61K 36/64
. . .
Orobanchaceae (Broom-rape family) [2013-01]
A61K 36/65
. . .
Paeoniaceae (Peony family), e.g. Chinese peony [2013-01]
A61K 36/66
. . .
Papaveraceae (Poppy family), e.g. bloodroot [2013-01]
A61K 36/67
. . .
Piperaceae (Pepper family), e.g. Jamaican pepper or kava [2013-01]
A61K 36/68
. . .
Plantaginaceae (Plantain Family) [2013-01]
A61K 36/69
. . .
Polygalaceae (Milkwort family) [2013-01]
A61K 36/70
. . .
Polygonaceae (Buckwheat family), e.g. spineflower or dock [2013-01]
A61K 36/704
. . . .
Polygonum, e.g. knotweed [2013-01]
A61K 36/708
. . . .
Rheum (rhubarb) [2013-01]
A61K 36/71
. . .
Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal [2013-01]
A61K 36/714
. . . .
Aconitum (monkshood) [2013-01]
A61K 36/716
. . . .
Clematis (leather flower) [2013-01]
A61K 36/718
. . . .
Coptis (goldthread) [2013-01]
A61K 36/72
. . .
Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree [2013-01]
A61K 36/725
. . . .
Ziziphus, e.g. jujube [2013-01]
A61K 36/73
. . .
Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn [2013-01]
A61K 36/732
. . . .
Chaenomeles, e.g. flowering quince [2013-01]
A61K 36/734
. . . .
Crataegus (hawthorn) [2013-01]
A61K 36/736
. . . .
Prunus, e.g. plum, cherry, peach, apricot or almond [2013-01]
A61K 36/738
. . . .
Rosa (rose) [2013-01]
A61K 36/739
. . . .
Sanguisorba (burnet) [2013-01]
​
A61K 36/74
. . .
Rubiaceae (Madder family) [2024-05]
WARNING

​
A61K 36/742
. . . .
{Coffea, e.g. coffee} [2024-05]
WARNING

A61K 36/744
. . . .
Gardenia [2013-01]
A61K 36/746
. . . .
Morinda [2013-01]
A61K 36/748
. . . .
Oldenlandia or Hedyotis [2013-01]
A61K 36/75
. . .
Rutaceae (Rue family) [2013-01]
A61K 36/752
. . . .
Citrus, e.g. lime, orange or lemon [2013-01]
A61K 36/754
. . . .
Evodia [2013-01]
A61K 36/756
. . . .
Phellodendron, e.g. corktree [2013-01]
A61K 36/758
. . . .
Zanthoxylum, e.g. pricklyash [2013-01]
A61K 36/76
. . .
Salicaceae (Willow family), e.g. poplar [2013-01]
A61K 36/77
. . .
Sapindaceae (Soapberry family), e.g. lychee or soapberry [2013-01]
A61K 36/78
. . .
Saururaceae (Lizard's-tail family) [2013-01]
A61K 36/79
. . .
Schisandraceae (Schisandra family) [2013-01]
A61K 36/80
. . .
Scrophulariaceae (Figwort family) [2013-01]
A61K 36/804
. . . .
Rehmannia [2013-01]
A61K 36/808
. . . .
Scrophularia (figwort) [2013-01]
A61K 36/81
. . .
Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed [2013-01]
A61K 36/815
. . . .
Lycium (desert-thorn) [2013-01]
A61K 36/82
. . .
Theaceae (Tea family), e.g. camellia [2013-01]
A61K 36/83
. . .
Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo [2013-01]
A61K 36/835
. . . .
Aquilaria [2013-01]
A61K 36/84
. . .
Valerianaceae (Valerian family), e.g. valerian [2013-01]
A61K 36/85
. . .
Verbenaceae (Verbena family) [2013-01]
A61K 36/855
. . . .
Clerodendrum, e.g. glorybower [2013-01]
A61K 36/86
. . .
Violaceae (Violet family) [2013-01]
A61K 36/87
. . .
Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine [2013-01]
A61K 36/88
. .
Liliopsida (monocotyledons) [2013-01]
A61K 36/882
. . .
Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus [2013-01]
A61K 36/884
. . .
Alismataceae (Water-plantain family) [2013-01]
A61K 36/886
. . .
Aloeaceae (Aloe family), e.g. aloe vera [2013-01]
A61K 36/888
. . .
Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage [2013-01]
A61K 36/8884
. . . .
Arisaema, e.g. Jack in the pulpit [2013-01]
A61K 36/8888
. . . .
Pinellia [2013-01]
A61K 36/889
. . .
Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto [2013-01]
A61K 36/8895
. . . .
Calamus, e.g. rattan [2013-01]
A61K 36/89
. . .
Cyperaceae (Sedge family) [2013-01]
A61K 36/8905
. . . .
Cyperus (flatsedge) [2013-01]
A61K 36/894
. . .
Dioscoreaceae (Yam family) [2013-01]
A61K 36/8945
. . . .
Dioscorea, e.g. yam, Chinese yam or water yam [2013-01]
A61K 36/896
. . .
Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus [2013-01]
A61K 36/8962
. . . .
Allium, e.g. garden onion, leek, garlic or chives [2013-01]
A61K 36/8964
. . . .
Anemarrhena [2013-01]
A61K 36/8965
. . . .
Asparagus, e.g. garden asparagus or asparagus fern [2013-01]
A61K 36/8966
. . . .
Fritillaria, e.g. checker lily or mission bells [2013-01]
A61K 36/8967
. . . .
Lilium, e.g. tiger lily or Easter lily [2013-01]
A61K 36/8968
. . . .
Ophiopogon (Lilyturf) [2013-01]
A61K 36/8969
. . . .
Polygonatum (Solomon's seal) [2013-01]
A61K 36/898
. . .
Orchidaceae (Orchid family) [2013-01]
A61K 36/8984
. . . .
Dendrobium [2013-01]
A61K 36/8988
. . . .
Gastrodia [2013-01]
A61K 36/899
. . .
Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane [2013-01]
A61K 36/8994
. . . .
Coix (Job's tears) [2013-01]
A61K 36/8998
. . . .
Hordeum (barley) [2013-01]
A61K 36/90
. . .
Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla [2013-01]
A61K 36/902
. . .
Sparganiaceae (Bur-reed family) [2013-01]
A61K 36/904
. . .
Stemonaceae (Stemona family), e.g. croomia [2013-01]
A61K 36/906
. . .
Zingiberaceae (Ginger family) [2013-01]
A61K 36/9062
. . . .
Alpinia, e.g. red ginger or galangal [2013-01]
A61K 36/9064
. . . .
Amomum, e.g. round cardamom [2013-01]
A61K 36/9066
. . . .
Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger [2013-01]
A61K 36/9068
. . . .
Zingiber, e.g. garden ginger [2013-01]
​
A61K 38/00
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergot alkaloids of the cyclic peptide type A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00) [2016-05]
NOTES

  • The terms or expressions used in this group follow exactly the definitions given in Note (1) following the title of subclass C07K.
  • Preparations containing fragments of peptides or peptides modified by removal or addition of amino acids, by substitution of amino acids by others, or by combination of these modifications are classified as the preparations containing parent peptides. However, preparations containing fragments of peptides having only four or less amino acids are also classified in groups A61K 38/05 - A61K 38/07.
  • Preparations containing peptides prepared by recombinant DNA technology are not classified according to the host, but according to the original peptide expressed, e.g. preparations containing HIV peptide expressed in E. coli are classified with the preparations containing HIV peptides.
  • This group covers also medicinal preparation containing DNA or RNA encoding for peptides as active ingredient.
  • Documents relating to new peptides, e.g. enzymes, or new DNA or RNA encoding for peptides and their use in medicinal preparations are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes relating to their medical uses.
A61K 38/005
.
{Enzyme inhibitors (protease inhibitors A61K 38/55)} [2013-01]
A61K 38/01
.
Hydrolysed proteins; Derivatives thereof [2013-01]
A61K 38/011
. .
{from plants} [2013-01]
A61K 38/012
. .
{from animals} [2013-01]
A61K 38/014
. . .
{from connective tissue peptides, e.g. gelatin, collagen} [2013-01]
A61K 38/015
. . . .
{from keratin} [2013-01]
A61K 38/017
. . .
{from blood} [2013-01]
A61K 38/018
. . .
{from milk} [2013-01]
A61K 38/02
.
Peptides of undefined number of amino acids; Derivatives thereof [2013-01]
A61K 38/03
.
Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof [2013-01]
A61K 38/04
.
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K 38/005;} gastrins {A61K 38/2207}, somatostatins A61K 38/31, melanotropins A61K 38/34 {; protease inhibitors A61K 38/55}) [2023-08]
A61K 38/043
. .
{Kallidins; Bradykinins; Related peptides} [2013-01]
A61K 38/046
. .
{Tachykinins, e.g. eledoisins, substance P; Related peptides} [2013-01]
A61K 38/05
. .
Dipeptides [2013-01]
A61K 38/06
. .
Tripeptides [2013-01]
A61K 38/063
. . .
{Glutathione} [2013-01]
A61K 38/066
. . .
{TRH, thyroliberin, thyrotropin releasing hormone} [2013-01]
A61K 38/07
. .
Tetrapeptides [2013-01]
A61K 38/08
. .
Peptides having 5 to 11 amino acids {(A61K 38/043 - A61K 38/046 take precedence)} [2021-08]
A61K 38/085
. . .
{Angiotensins} [2013-01]
A61K 38/09
. . .
Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides [2016-08]
A61K 38/095
. . .
Oxytocins; Vasopressins; Related peptides [2021-08]
A61K 38/10
. .
Peptides having 12 to 20 amino acids {(A61K 38/043 - A61K 38/046 take precedence)} [2016-05]
A61K 38/105
. . .
{Bombesin; Related peptides} [2013-01]
A61K 38/12
. .
Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K 38/043 - A61K 38/046 take precedence)} [2016-05]
A61K 38/13
. . .
Cyclosporins [2013-01]
A61K 38/14
. .
Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin} [2016-08]
A61K 38/15
. .
Depsipeptides; Derivatives thereof [2013-01]
A61K 38/16
.
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K 38/005)} [2013-01]
A61K 38/162
. .
{from virus} [2013-01]
A61K 38/164
. .
{from bacteria} [2013-01]
A61K 38/166
. . .
{Streptokinase} [2013-01]
A61K 38/168
. .
{from plants} [2013-01]
A61K 38/17
. .
from animals; from humans {(enzyme inhibitors A61K 38/005)} [2013-01]
A61K 38/1703
. . .
{from vertebrates} [2020-05]
A61K 38/1706
. . . .
{from fish} [2013-01]
A61K 38/1709
. . . .
{from mammals} [2013-01]
A61K 38/1716
. . . . .
{Amyloid plaque core protein} [2020-05]
A61K 38/1719
. . . . .
{Muscle proteins, e.g. myosin or actin} [2020-05]
A61K 38/1722
. . . . .
{Plasma globulins, lactoglobulins} [2020-05]
A61K 38/1725
. . . . .
{Complement proteins, e.g. anaphylatoxin, C3a or C5a} [2020-05]
A61K 38/1729
. . . . .
{Cationic antimicrobial peptides, e.g. defensins} [2020-05]
A61K 38/1732
. . . . .
{Lectins} [2020-05]
A61K 38/1735
. . . . .
{Mucins, e.g. human intestinal mucin} [2020-05]
A61K 38/1738
. . . . .
{Calcium binding proteins, e.g. calmodulin} [2020-05]
A61K 38/1741
. . . . .
{alpha-Glycoproteins} [2020-05]
A61K 38/1745
. . . . .
{C-reactive proteins} [2020-05]
A61K 38/1748
. . . . .
{Keratin; Cytokeratin} [2020-05]
A61K 38/1751
. . . . .
{Bactericidal/permeability-increasing protein [BPI]} [2020-05]
A61K 38/1754
. . . . .
{Insulin-like growth factor binding proteins} [2020-05]
A61K 38/1758
. . . . .
{p53} [2020-05]
A61K 38/1761
. . . . .
{Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2} [2020-05]
A61K 38/1767
. . .
{from invertebrates} [2013-01]
A61K 38/177
. . .
{Receptors; Cell surface antigens; Cell surface determinants} [2013-01]
A61K 38/1774
. . . .
{Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)} [2013-01]
A61K 38/1777
. . . .
{Integrin superfamily} [2013-01]
A61K 38/178
. . . .
{Lectin superfamily, e.g. selectins} [2013-01]
A61K 38/1783
. . . .
{Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors} [2013-01]
A61K 38/1787
. . . .
{for neuromediators, e.g. serotonin receptor, dopamine receptor} [2013-01]
A61K 38/179
. . . .
{for growth factors; for growth regulators} [2013-01]
A61K 38/1793
. . . .
{for cytokines; for lymphokines; for interferons} [2013-01]
A61K 38/1796
. . . .
{for hormones (for neuromediators A61K 38/1787)} [2013-01]
A61K 38/18
. . .
Growth factors; Growth regulators [2013-01]
A61K 38/1808
. . . .
{Epidermal growth factor [EGF] urogastrone} [2013-01]
A61K 38/1816
. . . .
{Erythropoietin [EPO]} [2013-01]
A61K 38/1825
. . . .
{Fibroblast growth factor [FGF]} [2013-01]
A61K 38/1833
. . . .
{Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II} [2013-01]
A61K 38/1841
. . . .
{Transforming growth factor [TGF]} [2013-01]
A61K 38/185
. . . .
{Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3} [2013-01]
A61K 38/1858
. . . .
{Platelet-derived growth factor [PDGF]} [2013-01]
A61K 38/1866
. . . . .
{Vascular endothelial growth factor [VEGF]} [2013-01]
A61K 38/1875
. . . .
{Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor} [2013-01]
A61K 38/1883
. . . .
{Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor} [2013-01]
A61K 38/1891
. . . .
{Angiogenesic factors; Angiogenin} [2015-09]
A61K 38/19
. . .
Cytokines; Lymphokines; Interferons [2013-01]
A61K 38/191
. . . .
{Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta} [2016-08]
A61K 38/193
. . . .
{Colony stimulating factors [CSF]} [2013-01]
A61K 38/195
. . . .
{Chemokines, e.g. RANTES} [2013-01]
A61K 38/196
. . . .
{Thrombopoietin} [2013-01]
A61K 38/20
. . . .
Interleukins [IL] [2013-01]
A61K 38/2006
. . . . .
{IL-1} [2013-01]
A61K 38/2013
. . . . .
{IL-2} [2013-01]
A61K 38/202
. . . . .
{IL-3} [2013-01]
A61K 38/2026
. . . . .
{IL-4} [2013-01]
A61K 38/2033
. . . . .
{IL-5} [2013-01]
A61K 38/204
. . . . .
{IL-6} [2013-01]
A61K 38/2046
. . . . .
{IL-7} [2013-01]
A61K 38/2053
. . . . .
{IL-8} [2013-01]
A61K 38/206
. . . . .
{IL-9} [2013-01]
A61K 38/2066
. . . . .
{IL-10} [2013-01]
A61K 38/2073
. . . . .
{IL-11} [2013-01]
A61K 38/208
. . . . .
{IL-12} [2013-01]
A61K 38/2086
. . . . .
{IL-13 to IL-16} [2013-01]
A61K 38/2093
. . . . .
{Leukaemia inhibitory factor [LIF]} [2013-01]
A61K 38/21
. . . .
Interferons {[IFN]} [2013-01]
A61K 38/212
. . . . .
{IFN-alpha} [2013-01]
A61K 38/215
. . . . .
{IFN-beta} [2013-01]
A61K 38/217
. . . . .
{IFN-gamma} [2013-01]
A61K 38/22
. . .
Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K 38/33, e.g. corticotropin A61K 38/35) [2013-01]
A61K 38/2207
. . . .
{Gastrins; Cholecystokinins [CCK]} [2013-01]
A61K 38/2214
. . . .
{Motilins} [2013-01]
A61K 38/2221
. . . .
{Relaxins} [2013-01]
A61K 38/2228
. . . .
{Corticotropin releasing factor [CRF] (Urotensin)} [2013-01]
A61K 38/2235
. . . .
{Secretins} [2013-01]
A61K 38/2242
. . . .
{Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin} [2013-01]
A61K 38/225
. . . .
{Calcitonin gene related peptide} [2013-01]
A61K 38/2257
. . . .
{Prolactin} [2013-01]
A61K 38/2264
. . . .
{Obesity-gene products, e.g. leptin} [2013-01]
A61K 38/2271
. . . .
{Neuropeptide Y} [2013-01]
A61K 38/2278
. . . .
{Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)} [2013-01]
A61K 38/2285
. . . .
{Endothelin, vasoactive intestinal contractor [VIC]} [2013-01]
A61K 38/2292
. . . .
{Thymosin; Related peptides} [2013-01]
A61K 38/23
. . . .
Calcitonins [2013-01]
A61K 38/24
. . . .
Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH] [2013-01]
A61K 38/25
. . . .
Growth hormone-releasing factor [GH-RF], i.e. somatoliberin [2024-01]
A61K 38/26
. . . .
Glucagons [2013-01]
A61K 38/27
. . . .
Growth hormone [GH], i.e. somatotropin [2024-01]
A61K 38/28
. . . .
Insulins [2013-01]
A61K 38/29
. . . .
Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides [2024-01]
A61K 38/30
. . . .
Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K 38/1754)} [2024-01]
A61K 38/31
. . . .
Somatostatins [2013-01]
A61K 38/32
. . . .
Thymopoietins [2013-01]
A61K 38/33
. . .
derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin [2013-01]
A61K 38/34
. . . .
Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin [2013-01]
A61K 38/35
. . . .
Corticotropin [ACTH] [2013-01]
A61K 38/36
. . .
Blood coagulation or fibrinolysis factors [2013-01]
A61K 38/363
. . . .
{Fibrinogen} [2013-01]
A61K 38/366
. . . .
{Thrombomodulin} [2013-01]
A61K 38/37
. . . .
Factors VIII [2013-01]
A61K 38/38
. . .
Albumins [2013-01]
A61K 38/385
. . . .
{Serum albumin} [2013-01]
A61K 38/39
. . .
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] [2013-01]
A61K 38/395
. . .
{Alveolar surfactant peptides; Pulmonary surfactant peptides} [2013-01]
A61K 38/40
. . .
Transferrins, e.g. lactoferrins, ovotransferrins [2013-01]
A61K 38/41
. .
Porphyrin- or corrin-ring-containing peptides [2013-01]
A61K 38/415
. . .
{Cytochromes} [2013-01]
A61K 38/42
. . .
Haemoglobins; Myoglobins [2013-01]
​
A61K 38/43
. .
Enzymes; Proenzymes; Derivatives thereof [2013-01]
NOTE

  • In this group,
    • proenzymes are classified with the corresponding enzymes;
    • enzymes are generally categorised according to the "Nomenclature and Classification of Enzymes" of the International Commission of Enzymes. Where appropriate, this designation appears in the subgroups below in parenthesis.
    • the specific enzyme(s) used are additionally classified in C12Y.
A61K 38/44
. . .
Oxidoreductases (1) [2013-01]
A61K 38/443
. . . .
{acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)} [2013-01]
A61K 38/446
. . . .
{Superoxide dismutase (1.15)} [2013-01]
A61K 38/45
. . .
Transferases (2) [2013-01]
A61K 38/46
. . .
Hydrolases (3) [2013-01]
A61K 38/465
. . . .
{acting on ester bonds (3.1), e.g. lipases, ribonucleases} [2013-01]
A61K 38/47
. . . .
acting on glycosyl compounds (3.2), e.g. cellulases, lactases [2013-01]
A61K 38/48
. . . .
acting on peptide bonds (3.4) [2013-01]
A61K 38/4806
. . . . .
{from animals other than mammals, e.g. snakes} [2013-01]
A61K 38/4813
. . . . .
{Exopeptidases (3.4.11. to 3.4.19)} [2013-01]
A61K 38/482
. . . . .
{Serine endopeptidases (3.4.21)} [2013-01]
A61K 38/4826
. . . . . .
{Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)} [2013-01]
A61K 38/4833
. . . . . .
{Thrombin (3.4.21.5)} [2013-01]
A61K 38/484
. . . . . .
{Plasmin (3.4.21.7)} [2013-01]
A61K 38/4846
. . . . . .
{Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)} [2013-01]
A61K 38/4853
. . . . . .
{Kallikrein (3.4.21.34 or 3.4.21.35)} [2013-01]
A61K 38/486
. . . . . .
{Elastase (3.4.21.36 or 3.4.21.37)} [2013-01]
A61K 38/4866
. . . . . .
{Protein C (3.4.21.69)} [2013-01]
A61K 38/4873
. . . . .
{Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H} [2013-01]
A61K 38/488
. . . . .
{Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E} [2013-01]
A61K 38/4886
. . . . .
{Metalloendopeptidases (3.4.24), e.g. collagenase} [2013-01]
A61K 38/4893
. . . . . .
{Botulinum neurotoxin (3.4.24.69)} [2013-01]
A61K 38/49
. . . . .
Urokinase; Tissue plasminogen activator [2013-01]
A61K 38/50
. . . .
acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase [2013-01]
A61K 38/51
. . .
Lyases (4) [2013-01]
A61K 38/52
. . .
Isomerases (5) [2013-01]
A61K 38/53
. . .
Ligases (6) [2013-01]
A61K 38/54
. . .
Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K 38/44 - A61K 38/46 or A61K 38/51 - A61K 38/53 [2016-05]
A61K 38/55
. .
Protease inhibitors [2013-01]
A61K 38/553
. . .
{Renin inhibitors} [2013-01]
A61K 38/556
. . .
{Angiotensin converting enzyme inhibitors} [2013-01]
A61K 38/56
. . .
from plants [2013-01]
A61K 38/57
. . .
from animals; from humans {(A61K 38/553, A61K 38/556 take precedence)} [2013-01]
A61K 38/58
. . . .
from leeches, e.g. hirudin, eglin [2013-01]
​​
A61K 39/00
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53) [2023-05]
NOTES

  • Groups A61K 39/002 - A61K 39/295 cover preparations containing protozoa, bacteria, viruses, or subunits thereof, e.g. membrane parts.
  • Preparation of antigen or antibody compositions is also classified in subclass C12N, if the step of cultivating the microorganism is of interest.
  • Documents relating to new peptides, e.g. enzymes, or new DNA or RNA encoding for peptides and their use in medicinal preparations are classified in subclass C07K or in group C12N 9/00 according to the peptides, with the appropriate indexing codes relating to their medical uses.
  • Documents relating to antibodies or DNA or RNA encoding for antibodies and their use in medicinal preparations are classified in group C07K 16/00 or in group C12N 9/0002 according to the antibodies, with the appropriate indexing codes relating to their medical uses.
  • Documents relating to new therapeutical uses of antibodies or DNA or RNA encoding for antibodies are classified in group C07K 16/00 or in group C12N 9/0002 according to the antibodies, with the appropriate indexing codes relating to their medical uses.
  • Documents relating to medicinal preparations containing different antibodies as active ingredients are classified in group C07K 16/00 according to the different active antibodies, with the appropriate indexing codes relating to their medical uses. However, documents relating to medicinal preparations containing antibodies and other compounds as active ingredients are classified in groups A61K 39/395 - A61K 39/42, in association with symbol A61K 2300/00 in Combination Sets.
WARNING

A61K 39/0001
.
{Archaeal antigens} [2013-01]
A61K 39/0002
.
{Fungal antigens, e.g. Trichophyton, Aspergillus, Candida} [2013-01]
A61K 39/0003
.
{Invertebrate antigens} [2013-01]
A61K 39/0005
.
{Vertebrate antigens (from snakes A61K 39/38)} [2013-01]
A61K 39/0006
. .
{Contraceptive vaccins; Vaccines against sex hormones} [2013-01]
A61K 39/0007
. .
{Nervous system antigens; Prions} [2013-01]
A61K 39/0008
. .
{Antigens related to auto-immune diseases; Preparations to induce self-tolerance} [2013-01]
A61K 39/001
. .
{Preparations to induce tolerance to non-self, e.g. prior to transplantation} [2013-01]
​
A61K 39/0011
. .
{Cancer antigens} [2023-05]
WARNING

​
A61K 39/001102
. . .
{Receptors, cell surface antigens or cell surface determinants} [2023-05]
WARNING

​
A61K 39/001103
. . . .
{Receptors for growth factors} [2023-05]
WARNING

​
A61K 39/001104
. . . . .
{Epidermal growth factor receptors [EGFR]} [2023-05]
WARNING

​
A61K 39/001106
. . . . .
{Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4} [2023-05]
WARNING

​
A61K 39/001107
. . . . .
{Fibroblast growth factor receptors [FGFR]} [2023-05]
WARNING

​
A61K 39/001108
. . . . .
{Platelet-derived growth factor receptors [PDGFR]} [2023-05]
WARNING

​
A61K 39/001109
. . . . .
{Vascular endothelial growth factor receptors [VEGFR]} [2023-05]
WARNING

​
A61K 39/00111
. . . . .
{Hepatocyte growth factor receptor [HGFR or c-met]} [2023-05]
WARNING

​
A61K 39/001111
. . . .
{Immunoglobulin superfamily} [2023-05]
WARNING

​
A61K 39/001112
. . . . .
{CD19 or B4} [2023-05]
WARNING

​
A61K 39/001113
. . . . .
{CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2} [2023-05]
WARNING

​
A61K 39/001114
. . . . .
{CD74, Ii, MHC class II invariant chain or MHC class II gamma chain} [2023-05]
WARNING

​
A61K 39/001116
. . . .
{Receptors for cytokines} [2023-05]
WARNING

​
A61K 39/001117
. . . . .
{Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30} [2023-05]
WARNING

​
A61K 39/001118
. . . . .
{Receptors for colony stimulating factors [CSF]} [2023-05]
WARNING

​
A61K 39/001119
. . . . .
{Receptors for interleukins [IL]} [2023-05]
WARNING

​
A61K 39/00112
. . . . .
{Receptors for interferons [IFN]} [2023-05]
WARNING

​
A61K 39/001121
. . . . .
{Receptors for chemokines} [2023-05]
WARNING

​
A61K 39/001122
. . . .
{Ephrin Receptors [Eph]} [2023-05]
WARNING

​
A61K 39/001124
. . . .
{CD20} [2023-05]
WARNING

​
A61K 39/001126
. . . .
{CD38 not IgG} [2023-05]
WARNING

​
A61K 39/001128
. . . .
{CD44 not IgG} [2023-05]
WARNING

​
A61K 39/001129
. . . .
{Molecules with a "CD" designation not provided for elsewhere} [2023-05]
WARNING

​
A61K 39/00113
. . .
{Growth factors} [2023-05]
WARNING

​
A61K 39/001131
. . . .
{Epidermal growth factor [EGF]} [2023-05]
WARNING

​
A61K 39/001132
. . . .
{Fibroblast growth factors [FGF]} [2023-05]
WARNING

​
A61K 39/001133
. . . .
{Platelet-derived growth factor [PDGF]} [2023-05]
WARNING

​
A61K 39/001134
. . . .
{Transforming growth factor [TGF]} [2023-05]
WARNING

​
A61K 39/001135
. . . .
{Vascular endothelial growth factor [VEGF]} [2023-05]
WARNING

​
A61K 39/001136
. . .
{Cytokines} [2023-05]
WARNING

​
A61K 39/001138
. . . .
{Tumor necrosis factors [TNF] or CD70} [2023-05]
WARNING

​
A61K 39/001139
. . . .
{Colony stimulating factors [CSF]} [2023-05]
WARNING

​
A61K 39/00114
. . . .
{Interleukins [IL]} [2023-05]
WARNING

​
A61K 39/001141
. . . .
{Interferons [IFN]} [2023-05]
WARNING

​
A61K 39/001142
. . . .
{Chemokines} [2023-05]
WARNING

​
A61K 39/001144
. . .
{Hormones, e.g. calcitonin} [2023-05]
WARNING

​
A61K 39/001148
. . .
{Regulators of development} [2023-05]
WARNING

​
A61K 39/001149
. . . .
{Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR} [2023-05]
WARNING

​
A61K 39/00115
. . . .
{Apoptosis related proteins, e.g. survivin or livin} [2023-05]
WARNING

​
A61K 39/001151
. . . . .
{p53} [2023-05]
WARNING

​
A61K 39/001152
. . .
{Transcription factors, e.g. SOX or c-MYC} [2023-05]
WARNING

​
A61K 39/001153
. . . .
{Wilms tumor 1 [WT1]} [2023-05]
WARNING

​
A61K 39/001154
. . .
{Enzymes} [2023-05]
WARNING

​
A61K 39/001156
. . . .
{Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]} [2023-05]
WARNING

​
A61K 39/001157
. . . .
{Telomerase or TERT [telomerase reverse transcriptase]} [2023-05]
WARNING

​
A61K 39/001158
. . . .
{Proteinases} [2023-05]
WARNING

​
A61K 39/001159
. . . . .
{Matrix metalloproteinases [MMP]} [2023-05]
WARNING

​
A61K 39/00116
. . . . .
{Serine proteases, e.g. kallikrein} [2023-05]
WARNING

​
A61K 39/001161
. . . . .
{Caspases} [2023-05]
WARNING

​
A61K 39/001162
. . . .
{Kinases, e.g. Raf or Src} [2023-05]
WARNING

​
A61K 39/001163
. . . .
{Phosphatases} [2023-05]
WARNING

​
A61K 39/001164
. . . .
{GTPases, e.g. Ras or Rho} [2023-05]
WARNING

​
A61K 39/001166
. . .
{Adhesion molecules, e.g. NRCAM, EpCAM or cadherins} [2023-05]
WARNING

​
A61K 39/001168
. . . .
{Mesothelin [MSLN]}